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Abstract 
Streptococcus pneumoniae is the major cause of bacterial meningitis bringing morbidity and 
mortality as well as neurological sequelae. Following colonization, translocation across the blood-
brain barrier (BBB) is a critical step in the pathogenesis of meningitis. Many pharmaceutical 
approaches have been developed in order to fight these bacteria. However, a major hurdle to the 
treatment of pneumococcal meningitis is the necessity of therapeutics able to cross the BBB. 
Thereby, besides the discovery of novel drugs to treat pneumococcal meningitis, the development 
of novel drug delivery systems that can cross the BBB and release the therapeutic molecule into 
the brain are urgently required. Since the structure of the BBB is known, many approaches for 
brain targeting have been developed based on physiological transport mechanisms. Thus, the aim 
of this project consists in the development of an immunoliposome as a drug delivery system to 
treat pneumococcal meningitis. To achieve this goal, potential of the encapsulated liposomes with 
penicillin, ceftriaxone and vancomycin was explored. For that, the minimum inhibitory 
concentrations of the three encapsulated antibiotics were determined in several serotypes of S. 
pneumoniae. Then, an immunoliposome was developed through attachment of a BBB 
transmigrating single-domain antibody to the liposome surface.  Translocation studies were 
performed using a BBB in vitro model in order to prove the immunoliposome efficiency in 
crossing the BBB. This approach allowed the development of an immunoliposome able to target 
and cross the BBB, encapsulating antibiotics capable to fight S. pneumoniae. Briefly, the strategy 
developed in the present project resulted in an immunoliposome that could be a safer and 
moreefficient approach to treat pneumococcal meningitis and a promising candidate in the 
treatment of other central nervous system diseases.  
Keywords: meningitis; S. pneumoniae; antibiotics; single domain antibodies; blood-
brain barrier; immunoliposome;  
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Resumo alargado 
A meningite pode ser definida como um processo inflamatório que envolve as meninges, quer as 
do sistema nervoso central quer as da medula espinal. Dos vários tipos de meningite descritos, a 
bacteriana é considerada o tipo mais severo. Streptococcus pneumoniae é considerado um dos 
principais agentes patogénicos responsáveis por este tipo de meningite causando uma alta taxa de 
mortalidade e morbilidade, e sequelas neurológicas nos sobreviventes. S. pneumoniae é um 
patógeno humano que coloniza essencialmente a nasofaringe em crianças, sendo uma causa 
importante de infeções na infância. S. pneumoniae é uma bactéria Gram-positiva, que 
frequentemente expressa uma cápsula polissacarídea, que constitui um dos seus principais fatores 
de virulência. Até ao momento, um total de 98 tipos de polissacarídeos capsulares foram descritos 
diferindo serológica e estruturalmente entre si. Após a colonização, a translocação através da 
barreira hematoencefálica (BHE) é uma das etapas cruciais para a patogénese da meningite.  
Têm sido desenvolvidas várias abordagens farmacêuticas com o intuito de combater a infeção 
causada por S. pneumoniae. No entanto, um grande obstáculo ao tratamento da meningite 
pneumocócica é a necessidade de desenvolver terapêuticas capazes de atravessar a BHE. A 
estrutura da barreira hematoencefálica leva a concluir que para criar um tratamento eficiente para 
a meningite pneumocócica, é necessária uma abordagem constituída por duas partes essenciais: 
o desenvolvimento do medicamento com as propriedades antibacterianas e a tecnologia de 
direcionamento para permitir que a molécula atravesse a BHE e seja capaz de combater a infeção. 
O foco atual é encapsular antibióticos em formulações lipossomais aumentando a atividade 
antibacteriana e as propriedades farmacocinéticas o que vai trazer várias vantagens ao sistema de 
administração de medicamentos como, por exemplo: diminuição da toxicidade, alta atividade 
antimicrobiana contra patógenios, seletividade do alvo e uma melhor biodistribuição. Desta 
forma, o principal objetivo deste projeto é desenvolver um sistema de administração de fármacos 
capaz de atravessar a BHE e libertar antibióticos para combater a meningite pneumocócica.  
Para atingir esse objetivo, propomos uma nova abordagem que engloba as propriedades da 
administração de fármacos e o direcionamento específico de um imunolipossoma. Para que o 
imunolipossoma seja direcionado com sucesso para a BHE, dois anticorpos de pequeno domínio, 
nomeadamente FC5 [55]  e G3 (um sdAb recentemente selecionado pelo nosso grupo que é capaz 
de atravessar a barreira hematoencefálica), foram acoplados na superfície do lipossoma, 
permitindo o transporte do lipossoma através da BHE. O uso de anticorpos de pequeno domínio 
tem várias vantagens relativamente ao uso de IgG, devido ao seu tamanho reduzido, o que facilita 
o acesso ao alvo. Adicionalmente, estas moléculas são mais estáveis quando em circulação 
permitindo uma administração mais eficiente. Em suma, ao conjugar a capacidade de um 
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anticorpo de pequeno domínio específico para o direcionamento e translocação da BHE e o 
encapsulamento de antibióticos no lipossoma é possível criar um sistema capaz de superar os dois 
obstáculos no desenvolvimento de um tratamento para a meningite pneumocócica: a necessidade 
de uma terapêutica capaz de atravessar a BHE e as propriedades antimicrobianas necessárias para 
combater S. pneumoniae. Dessa forma, a libertação gradual dos antibióticos no foco da infeção, 
resulta num sistema eficiente de administração de medicamentos para o tratamento da meningite 
pneumocócica.  
Para o desenvolvimento do projeto foram encapsulados em lipossomas três dos antibióticos mais 
recorrentemente utilizados no tratamento desta infeção (penicilina, vancomicina e ceftriaxona) 
com o objetivo de explorar o seu potencial no tratamento da meningite pneumocócica. Para isso, 
a concentração inibitória mínima dos três antibióticos encapsulados foi determinada em vários 
serótipos de S. pneumoniae. Uma vez validada a eficiência dos lipossomas encapsulados, foi 
possível prosseguir para o desenvolvimento de um imunolipossoma.  
O primeiro passo para o seu desenvolvimento consistiu na expressão dos anticorpos de pequeno 
domínio em bactérias, e, seguidamente, a sua purificação. Uma vez obtidos os anticorpos , estes 
foram ligados à superfície do lipossoma. Para esta ligação foram otimizados dois métodos 
diferentes amplamente utilizados para o efeito: o método da biotina e o método da maleimide. 
Uma vez otimizados os métodos de ligação, os imunolipossomas obtidos pelos dois métodos 
foram sujeitos a estudos de translocação para avaliar a sua capacidade de atravessar a BHE. 
Os estudos de translocação foram realizados utilizando um modelo da BHE in vitro. Através 
destes estudos verificou-se que o método de ligação usando a biotina é um método de ligação 
mais eficaz permitindo uma maior translocação do imunolipossoma. Da mesma forma, foi 
possível concluir que o anticorpo G3 tem uma maior capacidade para atravessar a BHE quando 
comparado com o FC5.  
 Esta abordagem permitiu o desenvolvimento de um imunolipossoma capaz de atravessar a BHE 
encapsulando antibióticos capazes de combater S. pneumoniae. Resumidamente, a estratégia 
estudada no presente projeto resultou num imunolipossoma que poderá corresponder a uma  
abordagem mais segura e eficiente no tratamento da meningite pneumocócica e ser um candidato 
promissor no tratamento de outras doenças do sistema nervoso central. 
 
Palavras-chave: meningite; S. pneumoniae; antibióticos; anticorpos de pequeno domínio; 
barreira hematoencefálica; imunolipossoma;  
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Chapter 1 - Introduction 
1.1. Meningitis 
 
Meningitis is a central nervous system (CNS) disorder and can be defined as an inflammation of 
the meninges, the layered unit that covers the brain and the spinal cord responsible for 
maintenance and function of the central nervous system. The infection affects several parts of the 
CNS, particularly the arachnoid, the pia matter and the intervening cerebrospinal fluid (CSF). The 
clinical state of acute meningitis involves fever, headache, muscle pain, stomach cramps, 
vomiting, photophobia, diarrhea and chills. Some variations in symptoms occur according to the 
patient’s age. In an advanced state some severe complications can result in the death of the patient, 
some hours after the appearance of the first symptoms [1]. 
 
 
 
 
 
 
 
 
 
Meningitis is normally the result of an infection but can also occur due to some non- infectious 
agents. Thus, this disease can be classified in two different categories: infectious meningitis, a 
severe condition of the CNS in consequence of a microbial infection or non–infectious meningitis, 
which represents a small percentage of the cases [2]. Regarding infectious meningitis, the most 
common agents are bacteria (Haemophilus influenzae, Streptococcus pneumoniae and Neisseria 
meningitidis) and viruses (principally enteroviruses, and in a smaller extent human 
immunodeficiency virus and herpes simplex viruses). A few meningitis cases can also be caused 
by parasites (Strongyloides stercoralis, Naegleria fowleri and Acanthamoeba cantonensis) [3]. In 
an infectious meningitis, the pathogen begins a localized infection, for example in the respiratory 
tract, the skin, the nasopharynx, the gastrointestinal tract or genitourinary tract of the host. Once 
in these sites, the microbial agents invade the surrounding host defences acquiring access to the 
CNS, spreading to the brain using different approaches: hematogenous spread ( through the blood 
vessels to the subarachnoid space), direct spread (travel through the nerves leading to  the brain) 
or a defect on CNS structure allowing the microorganisms to easily enter the CNS [4]. Among all 
types of meningitis, bacterial meningitis is considered the most serious form of this disease. 
 
Figure 1.1:  Comparison between normal meninges and meninges affected 
by meningitis.  
Adapted from: [118]. 
2 
 
1.2. Bacterial Meningitis 
 
Bacterial meningitis is an important cause of mortality and morbidity, especially among children 
less than 5 years old [1]. This kind of meningitis can be acquired at the hospital, in consequence 
of invasive procedures, frequently called nosocomial bacterial meningitis, or spontaneously, in 
the community – due to community acquired bacteria. Regarding the community-acquired 
bacterial meningitis, this disease continues having a heavy toll, even in developed countries. The 
incidence of bacterial meningitis in children less than 5 years old is between 1:400 ( in less 
developed countries) and 1:2000 ( in developed countries) [5]. Although plenty antibacterial 
agents are being studied to fight this disease, meningitis fatality rates remain high. Additionally, 
in 10 to 20% of those who survive permanent sequelae are observed, such as mental retardation 
and epilepsy [6]. The most common agents of acute bacterial meningitis are S. pneumoniae 
(pneumococcus meningitis) and Neisseria meningitidis (meningococcus meningitis). Data from 
community-acquired bacterial meningitis show that S. pneumoniae is responsible for 50% of all 
cases, affecting all age groups and causing the most severe disease both in children and adults 
[7].  
 
1.3. Streptococcus pneumoniae – The pathogen  
 
Pneumococci is a human pathogen that colonizes the 
nasopharynx of young children being the main cause 
of childhood infections, predominantly on the 
respiratory tract, such as sinusitis and pneumonia. 
However, the pathogen  can also develop an invasive 
disease such as bacteraemia, sepsis and meningitis. 
[7]. S. pneumoniae is currently the main pathogen 
associated with bacterial meningitis and belongs to 
the viridans group of streptococci, characterized by 
gram-positive cocci. Its optimum growth conditions 
need 5% carbon dioxide and a source of catalase, 
Figure 1.2: Anatomical representation of the human brain and meningeal structures 
affected by bacterial meningitis. Adapted from [119]. 
Figure 1.3: Morphology of S. pneumoniae. 
Adapted from: Orio et al [120]. 
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requiring a complex media supplemented with blood [8]. Once in blood agar culture, S. 
pneumoniae develops colonies which are alpha-hemolytic, presenting a green halo [9].  
The morphology of S. pneumoniae is described as lancet-shaped cocci frequently surrounded by 
a polysacharide capsule. The capsule is the outermost layer of encapsulated S.pneumoniae and, 
to date, a total of 98 capsular polysaccharide (CPS) have been described based on serological 
differences[10]. According to previous studies, a serotype can be defined as pneumococcal strains 
that produce a CPS with unique properties, structurally and serologically. Instead, a serogroup is 
defined as a group of serotypes that share several serologic characteristics such as, for example, 
cross-reactive antibodies [10]. The CPS has long been considered  indispensable for 
pneumococcal virulence [11]. Indeed, spontaneous nonencapsulated strains are almost avirulent, 
though some strains have been associated with some superficial infections [12].The role of the 
capsule in virulence results from its antiphagocytic activity in non-immune hosts [13]. 
Additionally, the capsule is also responsible for colonization, inhibition of mechanical removal 
by mucus and is also crucial for preventing autolysis and decrease the susceptibility to antibiotics 
[14, 15].  
1.4. Streptococcus pneumoniae – Infection and colonization 
 
 S. pneumoniae is an important commensal of the human nasopharynx and its carriage is often 
assymptomatic. Although rare, pneumococcus colonization can develop into disease [16]. 
Transmission between individuals occurs essentially by sneezing and coughing. Once in its 
habitat, bacterial survival depends on several factors as: adherence, nutrition and replication. For 
a successful colonization in the niche, S. pneumoniae needs to overcome the host’s immune 
system and to compete with the other microorganisms that inhabit  the same niche [17].  
Colonization of the nasopharynx requires that bacteria reach the epitelial cell layer followed by 
degradation of the mucus (to prevent mucus entrapment), using exoglycosidases [18]. 
Additionally, S. pneumoniae produces pneumolysin, a toxin which function is to decrease the 
movement of epitelial cell cillia and intensify the bacterial adherence [19]. Some enzymes are 
also responsible for the success of this process as such as N-acetylglucosamine-deacetylase A and 
O-acetyl-transferase that inhibit the lysozyme which provides the degradation of the pathogen’s 
cell wall [20]. Progression to invasive pneumococcal disease (IPD)   is influenced by some risk 
factors. First of all, in order to develop an infection, carriage is necessary and normally the 
infection occurs in a month after the acquisition of a new serotype [21]. The individuals with the 
highest carriage rates are the young children that commonly develop IPD owing to some factors 
directly associated with infection in this age group (table 1.1) [22]. 
 
 
 
Host Factors 
Age (< 2 years) 
Co-infection ( essentially respiratory virus) 
Absence of pneumococcal vaccination 
Immunodeficiency 
Parental smoking 
Environmental factors Winter months 
Pathogen factors Acquisition of a new serotype 
Table 1.1: Factors that influence invasive pneumococcal disease in young children 
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Over the years, several studies have focused on the distribution of pneumococcal serotypes in 
different geographic areas and age groups. Most, if not all, serotypes are apparently capable of 
causing serious disease in humans. However, just a small number of serotypes are usually 
responsible for the majority of IPD [23]. The reason why differences are observed in the incidence 
of IPD in several geographic areas and group age is still unclear. Nevertheless, the patient age is 
one of the most important factors when considering the serotype distribution, which is comproved 
when analysing the main serotypes that cause IPD in children and in adults, in the same period 
and geographical area [24]. Before the introduction of vaccines, IPD serogroups 6, 14, 18 and 19 
were found essentially between young children, while serotype 3 was common among older 
adults [25]. In the case of serotype 11A, it is commonly carried in children but rarely causes IPD 
in this age group. On the other hand serotype 11A IPD is frequently found between adults and is 
also associated with a high mortality rate [26]. 
1.5. Streptococcus pneumoniae – Central nervous system invasion 
 
Bacterial meningitis occurs when pathogenic virulence factors overwhelm host defense 
mechanisms. The mechanism by which S. pneumoniae crosses the blood brain barrier (BBB) is 
not fully understood. Recent studies have described some hypothesis for this process, namely : 
(1) the destruction of the endothelial cell layers by pneumolysin [27] and (2) bacterial crossing of 
the BBB by transcytosis, a route designed to transport molecules from the apical to the basolateral 
side [28]. Usually, a large number of bacteria circulating in the blood is necessary for CNS 
invasion. Pneumococci reach the CNS using a hematogenous route from a distant focus such as 
the lower airways for instance in a patient with pneumonia, or by direct spread to the cerebrospinal 
fluid, when the entrance of bacteria occurs from an infectious focus near the CNS, as in the case 
of an otitis media. Once in the CNS, S. pneumoniae quickly multiplies, inducing in a strong 
immunological response. The BBB becomes more permeable, allowing the influx of a high 
number of leukocytes into the brain causing brain edema, ischemia, neuronal damage, intracranial 
hypertension and in some cases leading to the death of the patient [29]. In consequence of 
bacterial growth in the meningeal spaces, a secondary bacteraemia can occur contributing to 
morbidity [30].  
 
 
 
Figure 1.4:  Simplified description of colonization, infections and CNS invasion from Streptococcus 
pneumoniae. 
5 
 
1.6. Streptococcus pneumoniae meningitis – Prevention and Treatment 
 
During many years, infections caused by S. pneumoniae, mainly meningitis, have been treated 
using antibiotics. Therefore, the choice was essentially penicillin, a -lactam, which binds to 
penicillin-binding proteins (PBPs) compromising their activity- PBPs are enzymes that catalyse 
the last steps of peptidoglycan synthesis [31]. However, it was noticed the emergence of resistance 
to penicillin and other -lactam antibiotics in S. pneumoniae, due to the selective pressures 
associated with the disseminated use of antibiotics and the expansion of multiresistant S. 
pneumoniae. Consequently, other antibiotics have been used for pneumococcal meningitis 
treatment. For example, vancomycin, vancomycin inhibits polymerization (tansglycosylation) 
and cross-linking (pranspeptidation).In consequence of this inhibition the bacterial cell wall 
becomes weak and ultimately results in exposure of the intracellular components causing the 
death of bacteria [32]. The cephalosporins, such as ceftriaxone, are also used as an option to treat 
S. pneumoniae infections. Their mechanism of action is very similar to penicillin’s, forming a 
covalent bond with PBPs and causing cell lysis [33]. Despite the efforts in using different 
antibiotics, the resistance levels increased, which combined with the high disease burden has led 
to the need for preventing strategies. This prevention was accomplished by immunization with 
conjugate vaccines.  
Pneumococcal vaccines currently in use target the capsular polysaccharide of S. pneumoniae. 
Therefore, these vaccines provide specific protection against some specific serotypes [34]. 
Presently, there are several types of vaccines against S. pneumoniae. One of them is the 23-valent 
polysaccharide pneumococcal vaccine (PPSV23) that uses purified capsular polysaccharides [35]. 
This vaccine confers protection against 23 serotypes of S. pneumoniae 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 
9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F, and is given to adults 
with  65  years of age, in some countries such as USA, and its effectiveness is about 50-70% 
[36]. PPSV23 works providing T-cell independent immunity needing revaccination each 5 years 
after the first vaccination [37]. However, it was observed that PPSV23 has a low efficacy in 
infants and young children due to the poor immunogenicity of the capsular polysaccharide [38]. 
To overcome the PPSV23 low efficacy a new 
vaccine was produced. The pneumococcal 
conjugate vaccine (PCV) was designed by 
complexing the purified capsular 
polysaccharide with a carrier protein, 
CRM197 [39]. The first PCV approved was 
PCV7, containing seven purified capsular 
polysaccharides: 4, 6B, 9V, 14, 18C, 19F, 
23F. These serotypes were chosen since they 
were the main cause of IPD among children 
in USA. After the introduction of this 
vaccine a significant decrease in IPD caused 
by the serotypes included in the vaccine has 
been reported [40]. Changes in the IPD 
incidence were evaluated after 7 years of 
PVC7 use in USA in children and it was 
reported that only 2% of IPD in children 5 
years old were due to PCV7 serotypes. 
Additionally, other 6 non- PCV7 serotypes were responsible for 68% of IPD in this age group, 
Figure 1.5: S. pneumoniae serotypes covered in 
each pneumococcal conjugate vaccine. 
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resulting in their inclusion on new vaccines [41]. In the following years the development of PCV 
with additional serotypes coverage was observed. PCV10 was launched in 2008 in USA and 
Europe and this vaccine includes all the serotypes present in PCV7 plus 3 additional serotypes: 
1,5 and 7F. In 2010, PCV13 became available. It also includes all the serotypes in PCV7 plus 1, 
3, 5, 6A, 7F and 19A. The introduction of these two PCV’s was a consequence of epidemiological 
changes owing to serotype replacement. Recently, a new vaccine was launched, PCV15, which 
includes all the serotypes present in PCV13 and additionally 22F and 33F (figure 1.5) [42]. 
After the introduction of a pneumococcal conjugate vaccine a decreased in carriage of the 
serotypes included in the vaccine was observed. However, an increase of non-vaccine 
pneumococcal serotypes is occurring, in a process named serotype replacement [43]. 
Unfortunately, the number of serotypes that can be included in a vaccine produced by protein 
conjugation of pneumococcal polysaccharide is still limited. As a result, an universal vaccine has 
not been available, so far. This leads to conclude that besides the use of pneumococcal conjugates 
vaccines as prevention an effective treatment to pneumococcal meningitis is also necessary. 
1.6.1. Pneumococcal meningitis treatment – The limitation of the blood brain barrier 
Pneumococcal meningitis is a brain disorder, meaning that in order to develop an efficient 
treatment for this disease overcoming the blood BBB is required. The BBB is classified as a 
complex, dynamic and adaptable interface, which functions is to control the exchange of 
substances between the CNS and the blood, being 
an important component regarding the regulation of 
the influx and efflux of ions, oxygen and 
nutrients[44]. The endothelial cells that compose 
the BBB are distinct from the endothelial cells 
present in the other tissues for the presence of BBB-
specific transporters and receptor proteins to control 
the entrance and exit of metabolites. However, the 
complexity of the BBB formed by tight junctions 
between brain endothelial and endothelial cells limit 
the transport of therapeutic molecules between the 
blood and the CNS, creating the main obstacle for 
therapeutics delivery in the brain [45]. As a 
consequence, most pharmaceuticals are not able to 
cross the BBB in which are included >99% of large 
protein drugs and 98% of small-molecule drugs. To 
be able to penetrate the brain the molecule has to be 
lipid soluble, form < 8-10 hydrogen bonds with 
water and have a molecular weight between 400-500 Daltons [46].  
 
 
 
Figure 1.6: Blood-Brain barrier structure. 
Adapted from: [121]. 
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The structure and the characteristics of the BBB lead to conclude that to create an efficient 
treatment for pneumococcal meningitis, the pharmaceutical approach requires two essential parts: 
the drug component, with the antibacterial properties and the targeting technology to allow the 
molecule to cross the BBB and to treat the infection.  
Regarding the targeting technology,  a controlled transport is demanding and should not cause 
damage to the BBB [47]. Currently, the methods used for improving CNS delivery of biologics 
involve neurosurgical intervention, and 
hospitalization, leading to the necessity of 
expensive equipment, and only a small 
group of patients can be treated since these 
interventions  result in several side effects 
and a limited clinical benefit [48]. To 
develop a drug delivery system into the 
brain, in a safer and most efficient way, the 
use of the endogenous BBB transporters has 
been considered [50]. There are several 
categories of endogenous transporters, 
depending on the type of the transport they 
perform, and the size of the molecules 
transported. The carriers responsible for the 
transport of small molecules, for example 
glucose, amino acids and nucleoside, are 
normally highly specific, and can be divided 
into carrier-mediated transport (CMT), and 
active efflux transport (AET).  
Large molecules, such as insulin and transferrin  
are transported through receptor-mediated 
transcytosis (RMT) which relies on a vesicular 
transport through nonspecific micropinocytosis 
[49, 50]. This pathway is highly selective for BBB-
expressed receptors and is activated by molecules 
able to bind the RMT receptors, as antibodies. 
When the ligand binds to the receptor, in the 
luminal side of the brain endothelial cells (blood 
side), a subsequent receptor clustering is triggered 
followed by an invagination of the membrane, 
resulting in the formation of intracellular transport 
vesicles. These vesicles are subject to classification 
in the endocytic compartments resulting in ligand 
release on the brain side (abluminal surface) and 
the recycling of the receptor (figure 1.8). The 
currently RMT receptors used for targeting and BBB transport are due to the expression of several 
specific receptors, including insulin receptors, lactoferrin receptor, transferrin receptor, 
glutathione transporter and scavenger receptors class B type 1 [44]. Each of the different types of 
Figure 1.8: Receptor-mediated endocytosis. 
1: Representation of the RMT receptors; 2: Ligand 
binding and receptor clustering; 3: Endocytosis and 
vesicles trafficking through the cell; 5: Exocytosis of 
payload;  
: 
Figure 1.7: Schematic representation of main routes 
for molecular traffic across the BBB. 
Adapted from: [124].  
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transporters have different capacities and affinities to transport ligands from the blood to the brain 
[50, 51]. Currently, the focus is to discover ligands to these receptors. Several molecules, such as 
antibodies, are known as Trojan horses and specifically target the RMT receptors, allowing the 
transcytosis of macromolecules through the BBB. Antibodies targeting alternative RMT 
pathways are becoming a dominant drug-developing pipeline to increase the development of BBB 
penetrating therapeutics. However, the approaches currently available rely on targeting widely 
expressed receptors as the mentioned above which can in consequence mistargeting the drugs to 
other organs, generating safety risks. This leads to a weak selectivity resulting in a small fraction 
of the injected dose reaching the brain [52]. Therefore, in the last few years the focus is to identify 
new BBB RMT targets. 
1.6.2.  Recombinant antibodies and single domain antibodies as promising BBB 
crossing scaffolds   
An IgG antibody is composed by a pair of similar 
light (VL) and heavy (VH) chains. The light 
chains contain a constant domain and a variable 
one and the heavy chains contain three constant 
domains and one variable domain. The Fc 
constant region is responsible for the recruitment 
of effectors from the immune system. Molecular 
biology tools allow the use of IgG fragments, as 
single domain antibodies (sdAb). These are 
antibodies fragments of the heavy or light chains 
present in the IgGs having a size of 
approximately 13 kDa (figure 1.9). Even if the formats with the antibody constant domains are 
very stable, the use of sdAb brings several advantages: the small size, the potential transvascular 
brain delivery capability, the low-specific interaction with tissues that express Fc receptors, the 
low immunogenicity, and the high stability in conditions of high temperature, and pH variations 
[53]. To discover new antigen-ligand systems that can be used to overcome the BBB, a study 
using llama sdAb phage-display library was performed [54].Two sdAbs were selected, FC5 and 
FC44, that recognized the human cerebromicrovascular endothelial cells and had the capability 
to transmigrate the BBB [55]. Regarding to FC5, this sdAb has the advantage of presenting 
species cross reactivity and has been demonstrated to bind to rat, mouse and human endothelial 
cells [56]. FC5 starts the RMT process by binding the α(2,3)-siaglycoprotein receptor and its 
endocytosis is classified as a clathrin-mediated process [57]. A panel of sdAbs were efficiently 
selected and showed promising BBB crossing characteristics as a result of a currently ongoing 
project with the goal to identify new vectors for BBB drugs.  The chosen sdAbs were tested both 
in vitro an in vivo and G3 was selected as the sdAb with greatest BBB crossing properties. 
Figure 1.9: Schematic representation of a human 
IgG antibody and a single domain antibody. 
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1.7. Pneumococcal meningitis treatment – The therapeutic approach 
Several studies have been focused on the drug development 
and delivery in all areas of clinical research. Commonly, the 
antimicrobial properties are brought by antibiotics. However 
with the increase of antibiotic resistance among bacterial 
pathogens and the antibiotic toxicity in the host body, some 
researchers are focused in the improvement of the current 
available therapy in a new form: liposomal formulations 
[58]. Liposomes can be described as spherical vesicles 
composed by one or more phospholipids bilayers enclosing 
a water space (figure 1.10). The liposomal formulations are 
normally composed by phospholipids, cholesterol and 
sometimes they also contain lipoproteins. The diameter of the liposomes is between 0.02 to 10 
m [59]. The biophysical properties of the liposomes can be changed by modifying some aspects 
as the type and the composition of the lipids, the liposome fluidity, its size, the charge of the 
liposomal surface (positive, negative or neutral), and the sensitivity to temperature and pH [60, 
61]. Due to their unique psychochemical features, liposomes are able to incorporate both 
hydrophilic and lipophilic molecules. The use of liposomes as a nanocarrier in drug delivery 
brings advantages once their outer lipophilic membrane increases the permeability across 
membranes. The current focus is to encapsulate 
antibiotics in liposomal formulations, increasing the 
antibacterial activity and pharmacokinetic properties, 
bringing several advantages to the drug delivery 
system as for example: decreased toxicity, the high 
antimicrobial activity against pathogens, the target 
selectivity, and the improved biodistribution [60, 62]. 
The diversity of liposomal formulations allows the 
encapsulation of different antibiotics leading to 
therapeutic success. However, there is a major 
drawback in the use of conventional liposomal 
formulations. Since they have a high systemic plasma 
clearance, liposomes are quickly removed from the 
circulation by macrophages, right after the 
intravenous administration [63]. The half-life of the 
liposome in the circulation can be enhanced by coating the liposome surface with some molecules 
as gangliosides or polyethylene glycol (PEG). When the liposomes are coated with PEG they are 
commonly referred as sterically stabilized liposomes (figure 1.11). The incorporation of PEG 
brings some advantages to the liposomal formulation, since it is presumed that it avoids the 
binding to opsonin’s derivated from the plasma, resulting in the prevention of the recognition by 
phagocytic cells, allowing a long-circulation in the blood stream [64, 65]. Liposomes can also be 
used featuring an active targeting, which is accomplished by coupling targeting ligands to the 
surface resulting in an immunoliposome. 
 
  
Figure 1.10: Schematic illustration of 
a conventional liposome. 
Adapted from: [122]. 
Figure 1.11: Schematic representation of a 
sterically stabilized liposome. 
Adapted from: [122]. 
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1.8. Immunoliposomes – combining the therapeutic approach with the targeting 
technology 
Immunoliposomes are a promising liposome approach designed to enhance the therapeutic 
effect of pharmaceutical agents as well as improve the in vivo targeting.  For that, specific ligands 
are attached to the liposome surface, able to recognize cellular surface antigens or receptors in 
targeted tissues [66]. The immunoliposomes combine the use of a pharmaceutical agent 
encapsulated in liposomal formulations, acting as nanocarriers, with the biological targeting 
technology. Therefore, liposomes with antibodies on 
the surface are able to be selectively taken up by cells 
that overexpress the receptor for the ligand coupled, 
improving therapeutic outcome [67]. Currently, there 
are several strategies available for the preparation of 
long-circulating immunoliposomes, normally involving 
conjugation of  antibodies or their fragments to the 
distal end on the PEG (figure 1.12). Different 
approaches have been developed for this objective, 
including covalent and non-covalent methods. The most 
applied approach belongs to the category of covalent 
methods and is based on the reaction of sulfhydryl 
groups with maleimide groups which is consider a 
clean, fast and efficient process. Regarding the non-
covalent methods, the most widely used is the biotin-
streptavidin-biotin method, that is based on the strong 
biomolecular binding between these two molecules. In 
previous studies, it was demonstrated that the 
conjugation of streptavidin to liposomes results in a 
flexible system, able to be conjugated with a wide 
variety of biotinylated proteins [68, 69]. The first successfully developed immunoliposome was 
used to localize in acute canine myocardial infarction [70]. Recent studies showed that 
immunoliposomes have successfully accomplished target delivery to brain tumours [71]. The 
conjugation of liposomes with specific antibodies or sdAb with targeting properties to the CNS 
increases their efficacy [72]. Previous studies using a murine monoclonal antibody, OX-26, 
specific against the transferrin receptor conjugated to a PEG-liposome showed that the use of a 
immunoliposome as a drug delivery system does not cause any damage to the BBB integrity [73]. 
Additionally, efficacy studies of the immunoliposome’s, when loaded with daunorubicin, 
demonstrated that the OX-26-PEG-liposomes crossed the BBB faster when compared with free 
daunorubicin [74].  
 
 
 
 
 
Figure 1.12: Schematic representation of the 
Liposome- sdAb conjugates by two different 
methods. A non-covalent method - Biotin-
Streptavidin-Biotin - and a covalent method 
based on maleimide covalent ligation to 
sulfhydryl groups 
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1.9. Objective 
The main goal of this project was to develop a drug 
delivery system able of crossing the BBB and release 
antibiotics in the CSF to clear pneumococcal infection. To 
achieve this goal, we proposed a novel approach by 
addressing the properties of drug delivery and targeting of 
an immunoliposome encapsulated with antibiotics (figure 
1.13) 
Therefore, the first objective of this project was the 
optimization of the liposomal formulation in order to 
obtain the most appropriate properties to encapsulate the 
selected antibiotics. The second objective was the 
validation of the antimicrobial efficiency of these liposomes in S. pneumoniae. For that, the 
antimicrobial activity of the antibiotic-encapsulated liposomes was compared with that of the free 
drug by determining the minimum inhibitory concentration. 
After liposome optimization and the activity studies, the following goal was to ensure its transport 
through the BBB. The ligation of two single domain antibodies, namely FC5 [55] and G3 to the 
liposome surface was optimized. Two different approaches were tested for the sdAb conjugation 
to the liposome. The most proficient developed immunoliposome was selected for in vitro studies. 
The final step of this project was an efficacy study, using the in vitro BBB model aiming to 
validate the immunoliposome system. 
By conjugating the ability of a specific sdAb to cross the BBB, and encapsulation of antibiotics 
in the liposome, it was possible to create a system able to overcome the main obstacle in the 
development of a treatment for pneumococcal meningitis: the difficulty in cross the BBB and still 
have the antimicrobial properties required to fight S. pneumoniae. With this approach, we expect 
to be able to gradually release the antibiotics at the focus of the infection, creating an efficient 
drug delivery system for treatment of pneumococcal meningitis. 
 
 
 
 
 
 
 
Figure 1.13: Schematic representation 
of the immunoliposome encapsulated 
with antibiotic proposed for this project. 
Figure 1.14: Schematic representation of the main objectives aiming to develop the immunoliposome for 
pneumococcal meningitis. 
Conjugation of brain targeting 
sdAbs to liposomes  
Validation of the 
immunoliposomes as a drug 
delivery system by in vitro assays 
Antimicrobial efficacy studies 
of the antibiotic-encapsulated 
liposome against S. 
pneumoniae. 
Optimization of the liposomal 
formulation to encapsulate the 
antibiotics 
Development of a new 
immunoliposome drug delivery 
system for treatment of 
pneumococcal meningitis  
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Chapter 2 – Material and methods 
2.1. Liposomes 
The liposomes were formulated and prepared by Dra. Manuela Gaspar, in collaboration with the 
Galenic Pharmacy and Pharmaceutical Technology department from the Faculdade de Farmácia 
da Universidade de Lisboa (FFUL). The formulations were prepared using different proportions 
of dipalmitoyl phosphatidylglycerol (DPPG), phosphatidylcholine (PC), PEG, 
phosphatidylglycerol (PG), dipalmitoyl phosphatidylcholine (DPPC). Penicillin liposomes were 
prepared by an active method loading through a calcium acetate gradient. Vancomycin liposomes 
were prepared by a passive method. Both vancomycin and penicillin liposomes were prepared 
with 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid HEPES buffer, pH 7.4 Ceftriaxone 
liposomes were prepared by an active method using an ammonium sulphate gradient. These 
liposomes suspended in citrate buffer pH 5.0 (10 mM acid citric, 145 mM NaCl). 
2.2. Streptococcus pneumoniae growth curve 
The first step in this project was the elaboration of a growth curve with the reference strain in 
order to acquire knowledge about its growth conditions. S. pneumoniae (TIGR4) bacterial stock 
was cultured on Columbia agar + 5% sheep blood and incubated overnight at 37°C. Then, the 
colonies formed were inoculated in brain heart infusion (BHI) (Difco) medium and incubated at 
37ºC until the solution reached an optical density (O.D.) of approximately 0.1. The resulting 
inoculum was diluted in a proportion of 1:100, incubated at 37ºC and the O.D. was measured 
every 30 minutes during approximately 8 hours.   
2.3. Determination of minimum inhibitory concentration using alamarBlue  
2.3.1 AlamarBlue Assay 
AlamarBlue is a ready-to-use resazurin-based solution which function is to measure the bacteria 
viability when exposed to different compounds. The 
assay incorporates a reduction-oxidation (REDOX) 
indicator that undergoes a colour change in 
consequence of cellular metabolic reduction (figure 
2.1). The changes in viability can be measured by 
absorbance or fluorescence and the quantity formed 
is directly proportional to the number of living cells 
in the sample. AlamarBlue is added to the samples 
and incubated during 2 hours at 37ºC. Then, 
absorbance is monitored at 570 nm and 600 nm 
(figure 2.2). The cell/bacteria viability is determined 
using the formula below (equation 2.1), calculating 
the percent difference in reduction between cells treated with antibiotics and control cells. 
Equation 2.1: 
 Cell/bacteria viability =  
(OX)2 A1−(OX)1 A2 of test agent dilution
(OX)2A1−(OX)1A2 of untreated positive growth control
× 100 
Figure 2.1: REDOX reaction of resazurin to 
resorufin that produces fluorescence 
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Where,  
ox = molar extinction coefficient of AlamarBlue oxidized form 
A = absorbance of test wells  
A = absorbance of growth control well 
1 = 570 nm  
2 = 600 nm   
2.3.2 AlamarBlue assay optimization 
The conditions of the alamarBlue assay were optimized and for that S. pneumoniae was cultured 
in Columbia agar and incubated at 37ºC, overnight. The colonies were transferred to several 
broths: BHI, Muller-Hinton (MH), Todd Hewitt broth (THB) and C+Y, using different initial 
O.D. ‘s: 0.1, 0.2, 0.3, 0.4, 0.5.  
2.3.3 Minimum inhibitory concentration by broth dilution 
A first assay was performed to determine the best range of concentrations for the determination 
of the minimum inhibitory concentration using the reference strain (S. pneumoniae TIGR4). For 
that, bacteria were inoculated into an agar medium (Columbia agar + 5% sheep blood) and 
incubated with antibiotic  (penicillin, vancomycin and ceftriaxone) in several concentrations: 
120g/ml, 12g/ml, 3g/ml, 0.75g/ml, 0.1875g/ml and 0.0469g/ml. The best range of 
concentrations determined  for MIC determination were 0.09, 0.19, 0.38, 0.75, 1.5, 3, 6, 12, 24 
and 120 µg/mL for vancomycin (VCM) and ceftriaxone (CTX), instead for benzylpenicillin 
(PEN) two additional concentrations were determined 0.04 and 0.02 µg/mL (Sigma-Aldrich). The 
MIC determination to penicillin, ceftriaxone and vancomycin were determined by broth 
Figure 2.3: Minimum inhibitory concentration by broth dilutions of the antibiotics 
and the encapsulated liposomes with antibiotics workflow. 
Figure 2.2: Alamarblue bacteria viability assay workflow. 
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microdilution following CLSI procedures [75]. The plates were incubated for 16 hours and 
then 10% of AlamarBlue (Alfagene) was added to the plates in order to determine the antibacterial 
activity of the antibiotics The encapsulated liposomes and the empty liposomes were also tested 
in the same conditions (figure 2.3). 
2.4. Minimum inhibitory concentration by agar dilution method 
 Besides the assays performed with AlamarBlue, the liposomes efficacy was also determined by 
the agar dilution method, according to the described by Garcia et al.[76]. Bacteria were incubated 
in a 96-well plate containing different concentrations of antibiotic and antibiotic encapsulated 
liposomes of the three antibiotics in study, penicillin, vancomycin and ceftriaxone and incubated 
overnight in at 37ºC. Then, the samples were diluted in a series of vials to 100×, 1,000× and 
10,000×. In each agar plate, three drops of 10l of the respective dilution were placed and 
incubated overnight at 37ºC. In the following day, the colonies were counted and the colony 
forming units (CFU) per ml was determined using the formula below. 
  Equation 2.2: 𝐂𝐅𝐔 𝐦𝐥⁄ =
Number of colonies ×Dilution factor
Volume of culture plate
 
2.5. Cytoxicity assays  
2.5.1. Cytoxicity assays optimization 
To investigate the in vitro cytotoxicity of the liposomes, a mouse brain endothelial cell line 
bEnd.3 (ATCC- CRL-2299) was used. The cells were cultured in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (Gibco) and 1% with penicillin- 
streptomycin (VWR) and incubated in a humidified atmosphere (37ºC and 5% CO2) until it 
reached confluency. Cells were then seeded on 96-well plates, using 10,000 cells/well and 30,000 
cells/well, and incubated in the same growth conditions for 24 hours. These cells were then treated 
VCM liposomes (120 g/ml, 1.5g/ml) and incubated for 24 hours. To determine the cell viability 
AlamarBlue was added, in a final concentration of 10%, followed by an additional incubation 
period of 24 hours. The measurements were performed at =570 nm and = 600 nm. Cell viability 
was presented as a percentage of viability when compared with the positive control (cells without 
treatment) as previously described. The previous experience was repeated with the optimized 
parameter - number of cells: 10,000, using the antibiotics and the encapsulated liposomes with 
the antibiotics in study: vancomycin, penicillin and ceftriaxone in all the study concentrations.   
2.6. Antimicrobial liposomes efficacy in clinical isolates 
After evaluating the efficacy of the liposomes in the reference strain S. pneumoniae (TIGR4), the 
same method was used in isolates recovered from IPD in Portugal presenting different serotypes 
(table 2.1). These strains were kindly provided by Prof. Mário Ramirez and Prof. José Melo 
Cristino from Faculdade de Medicina da Universidade de Lisboa.  
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Table 2.1: Clinical isolates used for antibacterial efficacy 
 
 
 
 
 
 
2.7. Expression of sdAb - FC5 and G3 
 To obtain the sdAb necessary to link to the liposome and efficiently develop an 
immunoliposome, it was essential to express and purify the antibodies. For that, Escherichia coli 
BL21 (DE3) was transformed with the respective antibody clone in the pET21 vector and grown 
from a single fresh colony in SB medium (tryptone (PVL), yeast extract (PVL), MOPS 
(NZYtech), with 100 µg/mL of ampicillin and incubated overnight at 37ºC with agitation. The 
cells were then diluted in a ratio of 1:30 in fresh medium containing ampicillin and incubated at 
37ºC until O.D.600nm reached 0.6-0.8. Protein expression was induced with 0.6 mM of isopropyl 
β-D-1thiogalactopyranoside (AppliChem) and incubated at 19ºC overnight. After that, cells were 
centrifuged at 4ºC for 20 minutes at 1700 G and the pellet was resuspended in binding buffer (20 
mM phosphate buffer, 500mM NaCl, 5% glycerol and 5mM imidazole). To ensure a successful 
lysis, cells were sonicated (Bandelin, Sonoplus) for 8 minutes with 30 % output conditions during 
6 cycles. The lysates were centrifuged at 16000 G for 15 minutes at 4ºC. The supernatant (soluble 
fraction) was separated from the pellet and filtrated (with a 0.22M filter (VWR)). 
 2.8. Immobilized metal ion affinity chromatography of sdAb - FC5 and G3 
The sdAb purification was performed using an immobilized metal ion affinity chromatography 
(IMAC). The purification process was done on an AKTA system (GE healthcare) using a His-tag 
protein purification column HisTrap HP 5ml (GE healthcare). The decrease of non-specific 
interactions between the proteins and the matrix was performed through washing the column with 
high salt concentration buffers, with low imidazole concentration. For that, the column was 
washed with binding buffer, followed by the sample application in the same conditions of the 
equilibration. To recover the intended protein, a gradient of imidazole was performed using 
sequential steps of elution buffer (20 mM phosphate buffer, 500mM NaCl, 5% glycerol and 500 
mM of imidazole): 6%, 18%, 60% and 100%. The collected fractions were analysed sodium 
dodecyl sulphate polyacrylamide gel (SDS-PAGE) using two different techniques: coomassie 
staining and western blot. 
 
 
Clinical serotypes 
PP644 - Serotype1 
PP622- Serotype 3 
PP491- Serotype 6B 
PP537- Serotype 7F 
2009V2540S- Serotype 14 
2016V02555S- Serotype15B/C 
2008V1934S- Serotype 19A 
2012V1441S- Serotype 24F 
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2.9. SDS-PAGE 
 SDS-PAGE is an analytical method used to separate proteins according to their size. The system 
is composed by two different layers of acrylamide between glass plates. The stacking gel is the 
upper layer that includes the samples and is composed by 4% of acrylamide, 0.15M Tris-HCl pH 
6.5, 0.20% sodium dodecyl sulfate (SDS), 0.10% ammonium persulfate (APS) and 0.01% of N, 
N, N', N'-tetramethylethylenediamine (TEMED, Aplichem). The separating (or resolving) gel is 
composed by 12.5% acrylamide, 0.5M Tris-HCl pH 8.8, 0.20% SDS, 0.10% APS and 0.01% 
TEMED. All the samples used in SDS-PAGE follow the same principles of denaturation which 
consist on adding loading buffer dye (1X) with 20 mM dithiothreitol (DTT) and heating for 10 
minutes at 100º C. This allows the SDS to bind the hydrophobic regions and finish the 
denaturation process. After sample application, the electrophoresis was performed at 180 V using 
a Mini-Protean Electrophoresis System (Biorad). The gel was stained using to Coomassie 
Staining and Western Blot to detect the protein band.  
2.9.1. Coomassie staining 
 Coomassie staining is a technique commonly used to detect proteins on gels. This technique can 
detect all the proteins with 0.2 μg or more, allowing to determine the quality of the purification. 
After running the SDS-PAGE, the resulting gel was covered with coomassie blue solution (Bio-
rad) and incubated for 1 hour under gently shaking. The gel was distained overnight using 40% 
methanol, 10% acetic acid, and 50% H2O. The gel image was acquired using the Chemidoc™ 
XRS+ (Bio-Rad) system. 
2.9.2. Western blot 
Western blot refers to the separation of proteins by SDS-PAGE according to their size, followed 
by their transfer and immobilization to a membrane support, aiming to perform a selective 
detection with a specific antibody[77]. This technique is based on the transfer of proteins from a 
SDS-PAGE gel into a nitrocellulose membrane (Amersham). The components of the transfer 
cassette are: one piece of nitrocellulose membrane, two pieces of filter paper and two sponges per 
gel. The membrane is immersed in transfer buffer (25mM tris base, 192 mM glycine and 20% of 
methanol) for 5-10 minutes. The cassette was assembled for transfer as presented in figure 2.4. 
The proteins were transferred to the membrane 
in a transfer tank (BioRad), for 1 hour at 250 
mA. Following western blot transfer the 
membrane was blocked with 5% non-fat milk in 
PBS with 0.2% Tween 20 for 1 hour at room 
temperature under gently shaking. Afterwards, 
the membrane was washed 3 times with PBS 
0.2% Tween 20 for 10 minutes. The membrane 
was then incubated with the primary antibody: 
anti-his (Roche) in a 1:3000 dilution during 1 
hour at room temperature under gently shaking. 
Proteins were detected by chemiluminescence 
through Luminata Forte Western HRP (Merck 
Millipore, Darmstadt, Germany) and acquired 
using the ChemiDoc XRS+ imaging system (Bio-Rad). 
Figure 2.4: Western blot sandwich order prepared to 
place in gel holder cassette. Adapted from: [123] 
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2.10. Size exclusion chromatography (SEC) of sdAb - FC5 and G3 
Size exclusion chromatography separates molecules based on their size by filtration through a 
gel. Separation occurs when molecules of different sizes are included or excluded from the pores 
within the matrix, depending on the size of the pores [78]. The samples used in this purification 
were the collected fractions from the previous IMAC in which the sdAb was present in the correct 
size – positive fractions. Those fractions were then purified by SEC, using a Hiprep16/60 
Sephacryl S-100 HR (GE Healthcare). The SEC process starts with the equilibration of the 
column with PBS, followed by loading the sample in the column. The resulted fraction was 
analysed by SDS-PAGE and western blot and concentrated using an Amicon® Ultra-4 (Merck) 
with a cut-off of 3 kDa. 
2.11. sdAb- FC5 and G3 coupling to the liposome surface 
To choose the best/most efficient coupling protocol and to determine whether the chemical design 
may influence the biological performance, two different methods were evaluated: the 
biotin/streptavidin ligation and the thiol– maleimide, a covalent coupling.  
2.11.1. Biotin – Streptavidin ligation 
A non-covalent method widely used is the biotin-streptavidin-biotin method, that is based on the 
strong biomolecular binding between these two molecules. Streptavidin is a homotetramer with 
approximately 56 kDa from Streptomyces avidinni that binds up until four biotin molecules with 
a Kd =10-14M [79]. The biotin is bound in the active site of streptavidin by eight hydrogen bonds 
along with van der Waals interactions among non-polar groups [80].  
2.11.2 Antibody biotinylation 
To link the antibody (G3 or FC5) to the liposome, the antibody has primarily to be linked to biotin 
which can be conjugated with some molecules such as avidin and streptavidin. The biotinylation 
of the antibody was performed using the kit “EZ-Link™ Sulfo-NHS-LC-Biotinylation Kit” 
(Thermoscientific). The molar ratio of Sulfo-NHS-LC-Biotin to protein was optimized to obtain 
the most efficient level of incorporation. In an initial phase we tested different molar ratios: 1:2.5, 
1:5, 1:10, 1:20, 1:30. The first assays showed that the molar ratio 1:30 was the most efficient. To 
confirm the labelling of the protein, a western blot was done using Streptavidin-HRP antibody 
(Invitrogen) with a dilution of 1:7500.  
2.11.3 Liposome antibody conjugation   
The biotin-antibody conjugate was mixed with streptavidin at a molar ratio of 3:1 (mole 
antibody/mole streptavidin) and the mixture was incubated at room temperature for 20 minutes. 
The mixture was then incubated with the pre-formed biotin-liposomes in a molar ratio of 1:1 
(mole biotin in the liposome/ mole antibody biotinylated) at room temperature for 2 hours and 
later overnight at 4ºC. Non-attached sdAb was removed by centrifugation using a 100K 
membrane filter (Amicon® Ultra-4, Millipore). 
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To confirm the ligation of the sdAb to the liposome 
two methods were performed: a SDS-PAGE followed 
by a western blot using Streptavidin-HRP antibody (at 
1:7500 dilution) as primary antibody to properly 
identify the biotinylated proteins. In parallel, a 
Sandwich Enzyme-Linked Immunosorbent Assay 
(ELISA) was also performed. Briefly, polystyrene 96-
well plates were coated with anti-PEG (abcam) 
antibody (10 µg/ml) for 1 h at room temperature. 
After washing 5 times with 100µL PBS and blocking 
with 3% bovine serum albumin (BSA) (1 h, room 
temperature) samples and known concentrations of 
biotinylated compounds were applied for 1 h at room 
temperature. This step was also followed by washing 
5 times with PBS. Anti-His was added as second antibody (at 1:1000 dilution in 1 % BSA) during 
1 hour at room temperature.  2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), 
(Sigma-Aldrich) and peroxidase (PVL) were added to each plate, incubated during 30 minutes at 
room temperature and the O.D. measured at 405 nm. 
. 
2.11.4 Thiol-Maleimide antibody-liposome conjugation 
 The thiol-maleimide conjugation is a ligation approach that belongs to the category of covalent 
methods and is based on the reaction of sulfhydryl groups with maleimide groups which is 
considered a clean, fast and efficient process [81] (figure 2.6). 
 
The sdAbs FC5 and G3 were coupled to liposome employing the maleimide-thiol addition 
reaction. Thiol group (-SH) were introduced into the sdAbs by incubating with Traut’s reagent at 
a molar ratio of 1:10 in 25 mM HEPES buffer, pH 8.0, containing 3mM EDTA. The reaction was 
incubated for 1 hour, in the dark, at room temperature under gentle shaking. The unreacted Traut’s 
reagent was removed by using a desalting column (Zeba™ Spin Desalting Columns, Thermo 
Scientific). Thiolated sdAbs were then coupled to the pre-formed MAL-liposomes, in a molar 
Figure 2.6: Thiol-Maleimide conjugation: (A) The liposome is prepared containing maleimide; (B) The 
liposome previously prepared is reacted with the sdAb containing a thiol group previously incoporated in 
the sdAb using the Traut's reagent. 
(B) 
(A) 
 Figure 2.5: Representation of the ELISA 
process and its components. 
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ratio of 3:1 (mole antibody/mole liposome). This reaction occurred with gentle shaking, in the 
dark at 4ºC, overnight. Non-attached sdAb was removed by centrifugation using a 100K 
membrane filter. To confirm the ligation of the sdAb to the liposome through the thiol-maleimide 
conjugation method, SDS-PAGE followed by a western blot using Anti-His (at 1:3000 dilution) 
as primary antibody was performed to properly identify the biotinylated proteins. 
2.11.5 SdAb-liposome ligation efficiency 
The efficiency of the ligation between the antibodies and the liposome in both methods was 
determined through the quantification of the initial sdAb and the non-attached sdAb using the 
Bradford method. The calculations were performed using the formula below: 
𝐄𝐪𝐮𝐚𝐭𝐢𝐨𝐧 𝟐. 𝟑: 𝐋𝐢𝐠𝐚𝐭𝐢𝐨𝐧 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 =
µg sdAb total − µg sdAb non attached
µg sdAb total
 × 100 
 
2.11.6 Bradford Method 
The Bradford method is a colorimetric method used for protein quantification, classified as rapid 
and accurate [82]. The protein concentration of the samples is estimated using a reference to 
absorbances determined for several standard BSA dilutions (table 2.2).  
Table 2.2: BSA standard dilutions used for the determination of a standard curve 
 
 
 
 
 
 
 
To construct the standard curve for BSA concentration, 10 µL of each standard were mixed with 
300 µL of coomassie plus reagent (Thermofisher). The mixture was incubated for 10 minutes at 
room temperature and mixed in a plate shaker for 30 seconds. The absorbance was measured at 
595 nm with a plate reader (BioRad). A standard curve was prepared by plotting the measurement 
for each BSA standard versus its concentration in µg/mL and was used to determine the protein 
concentration in unknown samples.  
 
 
Dilution Final BSA concentration (µg/mL) 
A 2000 
B 1500 
C 1000 
D 750 
E 500 
F 250 
G 125 
H 25 
I 0 (Blank) 
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2.12. In vitro Blood-Brain Barrier Model 
To study the efficiency of the immunoliposomes in crossing the BBB, an in vitro model was 
performed, according to [83]. In this model, bEnd.3 cells were cultured in DMEM supplemented 
with 10% FBS and 1% penicillin-streptomycin. When confluence was reached the cells were 
harvested with trypsin and were cultured 4000 cells/well in tissue culture inserts (VWR) with a 
pore size of 1 µm. Aiming to reach a confluent monolayer, the cells were in culture for 11-14 
days and the medium changed each two days. When in culture, the cells develop tight junctions 
responsible for restricting the passage of molecules between the apex and the base of the model, 
simulating the BBB [84]. 
 
 
 
 
 
 2.12.1.  Translocation and integrity studies  
The integrity of the blood brain barrier was determined through the permeability of fluorescein 
isothiocyanate-conjugated dextran with molecular weight of 40 kDa (FD40). FD40 was diluted 
in transport buffer (glucose 1M, MgCl2 1M, HEPES 1M, BSA 3% and PBS 1X) to a final 
absorbance below 0.1. The probe was added to the apex and incubated for 2 hours. Then, the 
fluorescence intensity in the apex and in the base was measured at 495 excitation and 520 nm 
emission wavelengths using a microplate reader (FLUOstar OPTIMA BMG LABTECH). The 
percentage of FD40 translocation was used using the equation presented below. 
Equation 2.4: 𝐓𝐫𝐚𝐧𝐬𝐥𝐨𝐜𝐚𝐭𝐢𝐨𝐧 (%) =
Fi
FT
× 100    
 The cultures were only used for translocation studies when the integrity was higher than 95%. 
To study the transmigration capabilities of the immunoliposomes through the BBB, the 
immunoliposomes used were encapsulated with rhodaminde, a fluorescent protein. The 
immunolipossomes were previously diluted in DMEM without phenol red (VWR). 1.15 ng of 
immunoliposomes (considering the ratio of antibody) were added to the apical side of the in vitro 
model. The apex volume and the base volume were collected after 90 min, 3, 6, 16 and 24 hours, 
the fluorescence in those samples was measured separately in a microplate reader (FLUOstar 
OPTIMA BMG LABTECH) and the translocation were calculated using the equation 2.4. 
2.13. Statistical analysis 
Each experiment was performed in triplicate, for three samples in each group. All data   are 
presented as mean with standard error of the mean.  A one-way ANOVA statistical test followed 
by a Dunnett’s test or a Turkey’s was used to compare the BBB fluorescence measurement with 
the respective controls and with each other considering P 0.05. 
Figure 2.7: Schematic 
representation of the in vitro 
BBB model 
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Chapter 3 – Results and discussion 
3.1. Streptococcus pneumoniae growth curve 
In order to be able to test the liposome activity in S. pneumoniae, the bacterial growth conditions 
were optimized. Bacterial growth is a process that involves several anabolic and catabolic 
reactions. These reactions result in cell division. The cell division process is dependent of the 
medium conditions. In ideal conditions, some bacterial cells can divide in about 20 minutes, 
however when in some environments the cells can take longer [85]. The elaboration of a growth 
curve in the conditions further used is an important step to determine the growth characteristics 
of the bacteria in study.  
Four different growth phases can be observed within a bacterial growth curve: the lag phase, the 
log phase, the stationary phase and the death phase. The first one represents the phase in which 
the growth rate is essentially zero. This phase is thought to occur as a result of the physiological 
adaptation of the bacteria to the growth environment and is considered a transition to the 
exponential phase [86]. The second growth phase is the exponential or log phase that starts after 
the lag phase, in which an exponential growth is verified corresponding to the maximum  growth 
rate [87]. The third phase is the stationary phase where the bacterial number in the culture remains 
constant because some cells continue to divide while others die [88]. This phase is followed by a 
death phase where the bacterial number decreases. Even though the S.pneumoniae growth curve 
presents all the discussed phases, in the growth curve assay (figure 3.1A) it was only possible to 
distinguish three phases: the lag phase that occurs during the first two hours of growth, the log 
phase during three hours and the stationary phase which occur the three final hours of the assay. 
Through the exponential phase it is possible to calculate the doubling time defined as the time it 
takes for a bacterial division to occur (figure 3.1 B). The mathematically principle behind the 
increase of the number of cells in a bacterial culture is given by the following equation:  
• 𝑵 = 𝑵𝟎 𝒆
µ𝒕, where N is the number of cells after each division event, N0 is the number 
of cells in the initial inoculum, µ is the growth rate and t is the time that passed since the 
beginning of the experiment. 
• 𝑶. 𝑫. = 𝑶. 𝑫.𝟎 𝒆
µ𝒕, the previous formula can be converted in absorbance units. For data 
evaluation, the O.D. values obtained were converted in a logarithmic scale [89].  Using 
STATIONARY PHASE 
LOG PHASE 
LAG PHASE 
A 
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Figure 3.1: S.pneumoniae growth curve . (A) The optical density (O.D.600nm ) values (± standard deviation of 
Streptococcus pneumoniae  cultures in BHI, at 37ºC, are plotted as a function of time. (B) Growth curve in 
logarithmic scale. 
B 
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the line equation (y = 0.0029e0.0251x) is possible to determine the growth rate, µ. In S. 
pneumoniae growth curve, the growth rate is about 0.0251 min -1.  
• The doubling time, td, can be calculated using the following formula that relates the 
growth rate and the doubling time: µ =
ln 2
𝑡𝑑
. For S. pneumoniae the calculated doubling 
time is 28 minutes. The theoretical value of S. pneumoniae is about 20-30 minutes which 
can vary accordingly to the growth conditions. For example, when cultured in C+Y 
growth medium the doubling time is about 30 minutes [90]. For the conditions tested, the 
value obtained is consistent with the theoretical value present in the literature.  
 
3.2. AlamarBlue assay optimization 
Currently, several different methods are provided to determine bacterial MIC of antibacterial 
agents. Broth microdilution is often used for MIC determination of many antibiotics. For MIC 
determination by broth microdilution bacteria are inoculated into a liquid growth medium with 
several concentrations of an antimicrobial compound. However, problems may occur when 
determining the endpoint given that the turbidity is measured visually or using absorbance [91]. 
The use of liposomes in these assays may lead to false interpretations when measuring the 
turbidity since the liposomes confer turbidity to the samples. This problem can be solved using a 
colorimetric MIC method. AlamarBlue is a resazurin compound normally used to determine the 
cell viability. As a result of bacterial growth and metabolism, alamarBlue changes colour from 
blue to pink. However, some media can interfere with alamarBlue, invalidating the results. 
Therefore, two conditions were tested in this assay: the initial O.D.600 nm, and the medium. 
Concerning the initial O.D.600 nm, the optimization presented in the figure 3.2B demonstrated that 
the initial number of bacteria does not interfere in the results. Accordingly, an initial O.D.600 nm of 
0.1 was defined as the standard for the following assays. On the other hand, no differences were 
observed between the three media tested (figure 3.2A), so BHI was the medium selected since it 
is considered the reference medium for S. pneumoniae.  
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Figure 3.2: Alamar blue optimization assay. (A)- Difference in reduction between treated and control cells in 
viability assay with free ceftriaxone, in three different media: THB, BHI and MH; (B)- Percentage of Alamar blue 
reduced versus initial O.D. 600nm; 
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3.3. Minimum inhibitory concentration of the antibiotics by broth dilution  
The treatment of choice for pneumococcal meningitis has been penicillin, ceftriaxone or 
cefotaxime. However, due to the high incidence of resistance to penicillin G and 3rd generation 
cephalosporins it is recommended the administration of vancomycin along with penicillin or 
ceftriaxone [92]. Before liposome encapsulation the three antibiotics used in treatment of this 
infection were tested, using a range of concentrations between 0.09 -120 g/ml. The aim of this 
assay was the validation of 
alamarBlue as a colorimetric broth 
dilution protocol as well as to confirm 
the antimicrobial activity of the 
selected antibiotics. The results are 
shown in figure 3.3.   
The results are presented as the 
comparison between the growth in 
each concentration and the growth in 
the positive control. By comparing 
the antibacterial effect of the 
antibiotics in study at the same 
concentrations, it was observed that 
the antibiotics have a high growth 
inhibition of the bacteria. The 
obtained MICs for each antibiotic 
tested are summarized in table 3.1. 
Table 3.1: MIC obtained for antibiotics in study. 
 The results obtained above allowed the 
validation of the broth dilution protocol, using 
alamarBlue to measure the bacterial viability 
enabling to proceed to antibiotic 
encapsulation in liposomes.  The next step had 
the main goal of providing a better option for clinical treatment, since the liposomes, in theory, 
possess lower cytotoxicity than the free antibiotics. 
3.4. Liposomal formulations with encapsulated antibiotics 
 
Once the antimicrobial efficacy of the selected antibiotics was verified, the next step was its 
encapsulation. This process was performed in collaboration with Dra. Manuela Gaspar (FFUL) 
that optimized the liposome composition to obtain the maximum encapsulation efficiency. The 
physicochemical characteristics of the liposomal formulations obtained are presented in table 3.2. 
 
 
Antibiotic MIC obtained (g/ml) 
Penicillin  < 0.9 
Vancomycin  1.5 
Ceftriaxone < 0.9 
Figure 3.3: MIC determination, by a colorimetric method, of 
the antibiotics in study. Difference in reduction between treated 
and control cells in viability assay (±standard deviation) with free 
antibiotic (ceftriaxone, penicillin and vancomycin), in BHI 
medium.  
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Table 3.2: Physicochemical characterization of liposomal formulations. 
 
 
The main chemical compounds in liposome compositions are lipids and phospholipids. In the 
prepared formulations two different compositions were observed: in ceftriaxone and penicillin 
liposomes the lipids present were PC, PG and PEG. Vancomycin liposomes were composed by 
DPPC, DPPG and PEG. Another relevant characteristic when the liposomes are intended for 
therapeutic use is the mean size, which influences the pharmacokinetics of the vesicles. According 
to previous studies [94], the appropriated particle size range for long-circulating carriers when 
targeting the brain is between 50-200 nm. The formulations used for this study presented a particle 
size of about 120-130 nm, meaning that is they were in the recommend range. Besides the particle 
size, a successful liposomal formulation requires stability, which needs the preparation of 
homogenous populations of liposomes of a certain size. Thus, the polydispersity index (P.I.) is 
used to define the size range of the liposomes. Basically, the P.I. is a representation of the 
distribution of size populations in a given sample. The P.I. varies in a range of 0.0 and 1.0, where 
0.0 represents a uniform sample, regarding the particle size and 1.0 is a polydisperse sample with 
multiple particle sizes [95]. When considering drug delivery liposomal formulations, the P.I. 
should be around 0.3 or less, indicating a homogenous population of lipid-based carriers [96, 97], 
which is verified in all liposomal formulations in study since the maximum value obtained for 
P.I. was 0.2. 
The zeta potential is also a strong component in a liposome characterization. This parameter is 
described as the total charge that a particle acquires. The value of the zeta potential is normally 
used to conclude about the stability of a colloidal system. When the particles involved in the 
system have a large negative or positive zeta potential they will repel each other, inhibiting the 
aggregation process. Low zeta potential values will result in aggregation. The ideal value of zeta 
potential is about > +30 mV or < -30mV[98]. The zeta potential values obtained for the prepared 
liposomes were not consistent with the ideal values meaning that the liposomes have some 
tendency for aggregation. The ceftriaxone liposomes were considered the most stables. 
The last parameter to consider is the encapsulation efficiency (E.E) which is defined as the total 
amount of encapsulant antibiotic found in the liposome solution versus the total initial input of 
 
Formulation 
Lipid 
Composition 
(molar ratio) 
(AB /Lip) i 
(μg/μmol) 
(AB/Lip) f 
(μg/μmol) 
E.E.  
(%) 
 (μm) 
(P.I.) 
Zeta 
Potencial 
(mV) 
Loaded PEN PC: PG: PEG 
(76:19:5) 
138±2 64±2 46±2 0.12 
(<0.1) 
-8 ± 1 
Unloaded PC: PG: PEG 
(76:19:5) 
n.a. n.a. n.a. 0.12 
(<0.1) 
-5 ± 1 
Loaded VCM DPPC: DPPG: 
PEG 
(76:19:0.5) 
121±4 25±1 21±1 0.13 
(<0.1) 
-5 ± 1 
Unloaded DPPC: DPPG: 
PEG 
(76:19:0.5) 
n.a. n.a. n.a. 0.12 
(<0.1) 
-7± 1 
 
Loaded CTX 
 
PC:PG: PEG 
(8:2:0.5) 
99±3 11±3 11±3 0.13 
(<0.2) 
-18 ± 2 
Abbreviations: Encapsulation efficiency (E.E); Mean size (); Polydispersity Index (P.I.) Antibiotic (AB); 
Liposome (Lip); Non applicable (n.a);  
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encapsulant. In table 3.2 these values are expressed in µg of antibiotic per µmol of liposomes. 
The encapsulation efficiency depends of multiple factors regarding the liposome and the 
antibiotic. Concerning the encapsulated antibiotic, the encapsulation efficiency is affected by the 
hydrophilic and lipophilic properties, which can be observed in the liposomes prepared for this 
study where, for the same liposomal formulation, ceftriaxone and penicillin liposomes have 
different encapsulation efficiencies. Moreover, the liposome properties also influence the 
encapsulation efficiency, as for example the aqueous volume, the surface area and the preparation 
methods [99]. Different encapsulation efficiencies were obtained for the different liposomes 
prepared. Penicillin liposomes had the highest E.E. of 46%, followed by vancomycin liposomes 
with 21% and finally ceftriaxone liposomes with an E.E. of about 11 %. 
The previous analyses led us to conclude that the liposomal formulations encapsulated with the 
antibiotics were successfully prepared, allowing to proceed for the next step: the efficacy studies. 
 
3.5. Antibacterial activity of encapsulated liposomes in S. pneumoniae (TIGR4) 
 
3.5.1 Penicillin liposomes 
By comparing the antibacterial effect of the penicillin-encapsulated liposome at the same 
concentration of the free antibiotic (figure 3.4), it was verified that the free antibiotic has a lower 
MIC. This result is expected since the antibiotic is immediately in contact with the bacteria and 
the encapsulated liposome requires the release process. Nevertheless, the encapsulated liposomes 
efficiently inhibit the bacterial growth at concentrations above 1.50µg/ml. The empty liposome 
was also tested, and we also observed some inhibitions of the bacterial growth at the maximum 
concentrations tested.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: MIC determination by a colorimetric method, using penicillin compounds. The results are plotted 
as the difference in reduction between treated and control cells in viability assay (±standard deviation) with free 
antibiotic, empty liposome and liposome encapsulated antibiotic, in BHI medium. The amount of empty lip was 
equal to the encapsulated liposome. 
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The colony-forming results were 
performed to validate the alamarBlue 
assay. The results can be analyzed 
with the log CFU/mL values obtained for 
each concentration. As presented in 
figure 3.5, the free antibiotic has a 
higher efficacy when compared to the 
penicillin-encapsulated liposome. In 
all the antibiotic concentrations tested 
where it was seen bacterial growth, the 
log values for free penicillin and 
penicillin-encapsulated liposomes 
were very close, meaning that the 
inhibition efficacy of the two 
compounds was similar. 
 
3.5.2 Vancomycin liposomes 
Currently, there are no reports of S. pneumoniae with patterns of resistance to vancomycin. So, 
vancomycin is used for pneumococcal meningitis treatment along with beta-lactam and 
cephalosporin to fight resistant strains that cause infection. The antibacterial efficacy of the 
vancomycin liposome is presented in figure 3.6. By comparing the antibacterial effect of the free 
antibiotic and vancomycin-encapsulated liposomes in the same concentrations, it was observed 
that in almost every case, the vancomycin liposomes presented efficacy similar to that of the free 
antibiotic. However, the MIC for the free antibiotic is about 1.50 µg/mL and for the vancomycin 
liposomes is 3.00µg/mL. In a previous in vivo study [100], aiming to fight S. pneumoniae the 
results showed that the liposomes promoted an increased amount of antibiotic near the bacteria. 
These previous results combined with the low cytotoxicity of the liposomes and the targeting for 
the BBB is a promising therapeutic approach, even with a low efficacy of the vancomycin-
encapsulated liposomes when compared with the free antibiotic. 
Figure 3.5: CFU of Streptococcus pneumoniae after treatment 
with penicillin compounds. The free Pen and Pen-Liposomes were 
incubated with the bacteria for 8 hours. 
Figure 3.6: MIC determination by a colorimetric method using vancomycin compounds.   The results are plotted as 
the difference in reduction between treated and control cells in viability assay (±standard deviation) with free antibiotic, 
empty liposome and vancomycin-encapsulated liposome, in BHI medium. 
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 The colony-forming unit assay 
confirmed the results obtained in the 
efficacy study using alamarBlue. It is 
observed that for all the concentrations 
tested the antibacterial effect of the 
vancomycin liposome was better than 
the free antibiotic. A higher efficacy of 
the alamarBlue was noticed in 
comparison with the previous assay 
which is expected since the assay in agar 
plates is more sensitive.  
 
 
3.5.3 Ceftriaxone liposomes 
 By comparing the antibacterial effect of the ceftriaxone liposome at the same concentration of 
the free antibiotic (figure 3.8), it was verified that, similar to penicillin, the free antibiotic has a 
lower MIC when compared to the encapsulated liposome The ceftriaxone-encapsulated liposomes 
efficiently inhibit the bacterial growth at concentrations above 1.50µg/ml and the free antibiotic 
exhibits a MIC between 0.00 and 0.09 µg/ml. The empty liposome was also tested and in this case 
an increase of the bacterial growth was noticed. 
 
 
 
 
 
 
 
 
 
 
 
The colony-forming units results showed that the ceftriaxone liposomes have an antibacterial 
effect much lower than the free antibiotic, which supported the results obtained in the alamarBlue 
assays. This can be due to the lower encapsulation efficacy of this antibiotic. However, the 
ceftriaxone liposomes showed efficacy against S. pneumoniae in concentrations higher than 1.50 
g/ml concluding that the liposomal formulations encapsulated with ceftriaxone are also a 
promising therapeutic approach for pneumococcal meningitis.  
Figure 3.7: CFU of Streptococcus pneumoniae after treatment 
with vancomycin compounds. The free VCM and VCM-Liposomes 
were incubated with the bacteria for 8 hours. 
Figure 3.8: MIC determination by a colorimetric method using ceftriaxone compounds.   The results are 
plotted as the difference in reduction between treated and control cells in viability assay (±standard deviation) 
with free antibiotic, empty liposome and ceftriaxone-encapsulated liposome, in BHI medium. 
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Overall, the results obtained with AlamarBlue showed a good agreement with the results obtained 
by the colony-forming units, as already observed in previous studies [101]. AlamarBlue has 
already been successfully utilized to determine the susceptibility of several microorganisms to 
antibiotics, including gram-positive bacteria [102]. In our assay, the colorimetric method 
developed for the MIC determination by AlamarBlue was tested with three different antibiotics – 
penicillin, ceftriaxone and vancomycin. Considering the results, the colorimetric MIC method is 
a reliable method for the determination of antibiotic’s susceptibility in S. pneumoniae. 
Concerning the antimicrobial effect of the encapsulated liposomes, it was observed that in the 
three antibiotic-encapsulated liposomes, the determined MIC was higher than the MIC obtained 
for the free antibiotic. The obtained results are summarized in table 3.3.  
Table 3.3: MIC obtained for the antibiotic-encapsulated liposomes, compared with the free antibiotic and the 
empty liposome. 
 
 
 
 
 
Several liposomal formulations with encapsulated antibiotics have been previously evaluated for 
the treatment of bacterial infections. For example, for Staphylococcus aureus infections many 
vancomycin-encapsulated liposomes were prepared. One of the studies also obtained a lower 
efficacy for the liposomal preparation when compared to the free antibiotic [103]. Another study 
evaluated the in vitro and in vivo efficacy of vancomycin-encapsulated liposome in S. aureus. 
The in vitro results showed that the vancomycin-encapsulated presented a similar MICs when 
compared with the free vancomycin, but seemed to be more efficient in the in vivo studies [104]. 
The presented study does not address the comparison of the pharmacokinetics and biodistribution 
of the antibiotics-encapsulated liposomes and the free antibiotics. However, the liposome stability 
has been demonstrated to depend on the liposomal formulation characteristics, which already was 
discussed and proved to be a satisfactory formulation in all the cases.  
 MIC obtained (g/ml) 
 Free antibiotic Antibiotic 
encapsulated 
liposome 
Empty 
liposome 
Penicillin < 0.02 1.50 12.00 
Vancomycin 1.50 3.00 - 
Ceftriaxone < 0.09 1.50 - 
Figure 3.9: CFU of Streptococcus pneumoniae after treatment with 
ceftriaxone compounds. The free CTX and CTX-Liposomes were 
incubated with the bacteria for 8 hours. 
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The mechanism by which the liposomal formulations prepared inhibit S. pneumoniae growth is 
not established yet. The liposome can interact with the bacterial cell wall allowing an increased 
quantity of antibiotic to reach the cytoplasm. However, the time and process that leads to the 
antimicrobial activity of the liposome is not completely understood. The main advantages of the 
liposomes as nanocarriers for the pneumococcal meningitis is their ability to decrease the 
antibiotic toxicity and improve delivery of antibiotics to the brain[105]. The obtained MICs for 
the antibiotics-encapsulated liposome represent an auspicious approach for the treatment of 
pneumococcal meningitis. The most proficient liposomes developed are vancomycin-
encapsulated liposomes since the difference between the efficacy of the free antibiotic and the 
encapsulated liposome is lower when compared with the other two formulations prepared. It is 
also important to note that these encapsulated liposomes will be coupled with a ligand for the 
BBB, improving the amount of bacteria reaching the focus of infection. 
3.6 Antimicrobial efficacy of the liposomes in clinical isolates 
S. pneumoniae is a gram-positive bacterium surrounded by capsule that can differ in the 
polysaccharides, dividing S. pneumoniae in serotypes [10]. To further elucidate if the differences 
between the serotypes affect the interaction between the bacteria and the liposome and 
consequently the antibacterial efficacy of the liposome, the MIC was determined by broth dilution 
method for several serotypes recovered from IPD. The first goal of this study was to determine 
the MIC of the invasive S. pneumoniae strains isolated for the free antibiotic. These data allowed 
monitoring the efficacy of the liposomes accordingly to the patterns of resistance.   
Eight S. pneumoniae strains were collected from patients with IPD. The interpretation of MIC 
breakpoints was performed using the European Committee on Antimicrobial Susceptibility 
Testing (EUCAST) breakpoints. By evaluating the antimicrobial susceptibility (table 3.4), we 
observed that all strains were susceptible to vancomycin. On the contrary, two serotypes (19A 
and 14) showed antimicrobial resistance to ceftriaxone (MIC ≥ 2 µg/ml) and benzylpenicillin 
MIC ≥ 2 µg/ml). Serotype 19A is one of the most resistant serotypes to several antimicrobial 
agents, including ceftriaxone and penicillin which is supported by earlier reports. In accordance 
with the obtained results, serotype 14 is normally associated with a high resistance to penicillin 
antibiotics [106] [107]. Since the resistances of the strains were elucidated, the efficacy studies 
of the liposomes encapsulated with the three antibiotics in study were performed aiming to 
conclude about the influence of the several capsules in the presented therapeutics.  
Table 3.4: Resistance of the invasive S. pneumoniae serotypes isolated from IPD. The interpretation of the MIC 
breakpoints was performed using EUCAST breakpoints. The MIC breakpoints were determined by broth dilution as 
described in the material and methods section. 
S. pneumoniae 
serotype 
MIC (mg/L) Interpretation of MIC 
breakpoints  
 PEN VCM CTX PEN VCM CTX 
1 0.09 1.50 0.09 S S S 
3 0.04 0.75 0.38 S S S 
6B 0.02 1.50 0.19 S S S 
7F 0.04 1.50 1.50 S S S 
14 3.00 1.50 6.00 R S R 
15 B/C 0.04 0.75 0.75 S S S 
19A 120 1.5 12.0 R S R 
24F 0.19 1.5 0.09 S S S 
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3.6.1 Penicillin liposomes 
  
By comparing the minimum inhibitory concentration of the penicillin- encapsulated liposomes of 
the several serotypes it was possible to divide the serotypes in three groups according to the 
efficacy of the penicillin-encapsulated liposomes. The first group is composed by the serotypes 
7F and 15 B/C, both penicillin susceptible, and the results of the assay are similar to the results 
of the reference strain described above. The MIC for the free antibiotic calculated previously was 
about 0.04 g/ml. The results of these two serotypes are presented in figure 3.10, where is possible 
to observe that the MIC for the two serotypes is about 0.75 g/ml. 
According to these results it is possible to conclude that the penicillin-encapsulated liposomes are 
a promising therapeutic choice when considering meningitis caused by serotype 7F and serotype 
15B/C. 
The second group of serotypes with similarities between the results are serotypes 1, 3, and 6B. 
All of them are also penicillin susceptible with a MIC between 0.02-0.09 g/ml, as described in 
table 3.2. However, the results of the minimum inhibitory concentration by broth dilution have 
shown that the penicillin liposomes do not have an antibacterial effect on these serotypes, in all 
range of concentrations tested 
(figure 3.11). Since these 
strains are penicillin 
susceptible and the penicillin-
encapsulated liposomes had 
high efficacy in the reference 
strain and in serotypes 7F and 
15 B/C the results can be an 
effect of the differences 
between the capsular 
polysaccharide, which can 
improve the interaction 
between the liposome and the 
bacteria or in these cases  
inhibit this process.  
 
Figure 3.10: MIC determination by a colorimetric method using penicillin compounds in five different 
serotypes. Differences in reduction between treated and control cells in viability assay (±standard deviation) with 
penicillin-encapsulated liposomes, in serotype 7F and 15B/C (left image); in serotype 1,3 and 6B (right image) 
Figure 3.11: MIC determination by a colorimetric method using 
penicillin compounds in three different serotypes. Differences in 
reduction between treated and control cells in viability assay (±standard 
deviation) with penicillin-encapsulated liposomes, in serotypes 14, 
19A, and 24F. 
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The final three serotypes with similar results are serotypes 14, 19A and 24F. Serotypes 14 and 
19A are resistant to penicillin while serotype 24F is susceptible. The penicillin-encapsulated 
liposomes have similar antibacterial activity in the three serotypes, as observed in figure 3.11. In 
most of the concentrations the antibacterial effect of the liposomes was not noticed, except for 
the two higher concentrations. The MIC for these three serotypes was between 24-120 g/ml. 
3.6.2.  Vancomycin liposomes 
The antimicrobial effect of the encapsulated liposomes was also tested in the serotypes for 
vancomycin. In this case, none of the serotypes in study presented resistance patterns which imply 
that the differences in the results between the several serotypes are only a consequence of the 
differences in the biochemical characteristics of the polysaccharide capsule. 
The results of the minimum inhibitory concentration with the vancomycin-encapsulated 
antibiotics (figure 3.12) show that this nanocarrier can inhibit the growth of six different 
serotypes. However, in the case of serotypes 1, 3 and 6B, it is noticed that the maximum growth 
inhibition occurs at a concentration of 6.00 g/ml with a slight decrease in the inhibition in the 
higher concentrations. In the case of serotypes 14, 15B/C and 19A the maximum growth 
inhibition is also verified at 6.00 g/ml but the decrease of the inhibition in the higher 
Figure 3.12: MIC determination by a colorimetric method using vancomycin compounds in six different 
serotypes. Differences in reduction between treated and control cells in viability assay (±standard deviation) with 
vancomycin-encapsulated liposomes: in serotypes 1,3 and 6B (left image); in serotypes 14, 15B/C and 19A; 
Figure 3.13: MIC determination by a colorimetric method using vancomycin 
compounds in two different serotypes. Differences in reduction between treated 
and control cells in viability assay (±standard deviation) with vancomycin-
encapsulated liposomes: in serotypes 1,3 and 6B (left image); in serotypes 14, 
15B/C and 19A; 
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concentrations is more pronounced. At a vancomycin encapsulated liposome concentration of 120 
g/ml the antibacterial efficacy of the liposomes become negligible. On the other hand, the results 
for the serotypes 7F and 24F are presented in figure 3.13. In these cases, the vancomycin-
encapsulated liposomes do not affect the bacterial growth in any concentration tested, when 
compared with the positive control.  
3.6.3. Ceftriaxone liposomes 
Similar to penicillin liposomes, the comparison between the minimum inhibitory concentration 
of the ceftriaxone-encapsulated liposomes of the several serotypes resulted in a serotype division 
according to the efficacy of the ceftriaxone-encapsulated liposomes. In figure 3.14 the results for 
the strains of serotypes 1, 3 and 6B, all of them susceptible to ceftriaxone, are presented. The 
antimicrobial effect of the encapsulated liposomes was similar to the case of the penicillin., The 
antimicrobial efficacy of the ceftriaxone-encapsulated liposomes was detected in concentrations 
higher than 3.0 g/ml, which represent a satisfactory result in fighting these serotypes.  
In contrast, the effect of the ceftriaxone encapsulated liposomes in serotype 7F and serotype 14 
respectively, susceptible and resistant to ceftriaxone, are only noticed in the highest concentration 
tested (120 g/ml), which was expected for serotype 14 due to the resistance patterns but not in 
the case of serotype 7F. Once more, the low efficacy of the encapsulated liposomes can be a result 
Figure 3.14: MIC determination by a colorimetric method using ceftriaxone compounds in five different 
serotypes. Differences in reduction between treated and control cells in viability assay (±standard deviation) with 
ceftriaxone-encapsulates liposomes: in serotypes 1,3 and 6B (left image); in serotype 7F and 14 (right image); 
Figure 3.15: MIC determination by a colorimetric method using ceftriaxone compounds in three 
different serotypes. Differences in reduction between treated and control cells in viability assay (±standard 
deviation) with ceftriaxone-encapsulated liposomes, in serotypes 1,3 and 6B. 
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of the capsule characteristics that limits the interaction with the liposome. Finally, the 
antimicrobial effect of the encapsulated liposomes with ceftriaxone in the serotypes 19A, 24F and 
15B/C is presented in figure 3.15. The results show that the ceftriaxone-encapsulated liposomes 
are inefficient in all the range of the concentrations tested. 
 
The study of the antimicrobial efficacy of the encapsulated liposomes in clinical serotypes led to 
conclude that the efficacy of the nanocarrier is different according to the serotype in study. For 
the interpretation of the results it is necessary to take into consideration several factors than can 
affect the interaction between the liposome and the bacteria. The first factor to consider is the 
characteristics of the liposome. Besides the characteristics already discussed in chapter 3.4., some 
physicochemical characteristics are crucial, as for example: the surface charge (cationic, anionic 
or neutral), the proportion and type of lipids in the composition and the presence of long-
circulating molecules [108]. Concerning the bacteria, the role of the CPS in the interaction with 
the liposome is not fully understood. The assay with several serotypes was performed aiming to 
conclude about this interaction. The results obtained are summarized in table 3.5. 
 
 
 
 
 
 
 
 
 
 
These results obtained above showed that the different capsules influence the results for the same 
liposomal formulation. For example, in the liposomal formulation developed for encapsulation of 
penicillin characterized as a negative charged formulation composed by PC, PG and PEG, three 
susceptible serotypes do not get any inhibition of the bacterial growth. On the contrary, in two 
other serotypes the calculated MIC was 0.75 g/ml, revealing a high efficacy of the tested 
encapsulated liposome formulation. These results proved that the CPS influence the antibacterial 
effect of the developed liposomes. 
 
 
 
 
 
 
S. pneumoniae 
serotype 
Antibiotic- encapsulated 
liposome MIC (g/mL) 
  PEN VCM CTX  
1  n.a. 6 12  
3  n.a. 6 12  
6B  n.a. 6 12  
7F  0.75 n.a. 120  
14  120 6 n.a.  
15 B/C  0.75 6 n.a.  
19A  24 6 n.a.  
24F  120 n.a. n.a.  
Table 3.5: MIC obtained for the antibiotic-encapsulated 
liposomes, in several IPD isolated serotypes. 
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3.7 Cytotoxicity assays with free antibiotics and antibiotics-encapsulated liposomes 
 
Cytotoxicity assays are one of the most important 
parameters for biological evaluations since drugs 
have several cytotoxic mechanisms [109]. Aiming 
to evaluate the potential cytotoxicity effects of the 
free antibiotics and antibiotics-encapsulated 
liposomes on brain endothelial cells (bend.3), cells 
were treated with vancomycin-encapsulated 
liposomes with two different initial density of 
cells/per well, in order to find the best conditions 
for the cytotoxicity assay. The effect of the tested 
compound on cell viability was measured using 
alamarBlue as described in the material and 
methods section and three antibiotic 
concentrations (0.0, 1.5 and 120.0 g/ml). The 
results of the density cells optimization presented 
in figure 3.16 showed that the initial cells density 
does not affect the results and 10000 cells/per well was defined as the cell density standard for 
the assay.   
The same method was used to evaluate the cytotoxicity effects of all the compounds in study and 
are presented in figure 3.17. Regarding the vancomycin formulation and free antibiotics, it is 
possible to observe that there’s no evidence of toxicity in the range of concentrations tested. The 
Figure 3.16: Cytotoxicity assay - density cells 
optimization. Two different initial density cells were 
tested using three concentrations of vancomycin 
encapsulated liposomes.  
Figure 3.17: Antibiotic encapsulated liposomes cytotoxicity assays. Bend.3 cells were subjected to the concentrations 
in study of each liposomal formulation of the chosen antibiotics (vancomycin, penicillin and ceftriaxone). After 24 h 
treatment, cell viability was evaluated with AlamarBlue. Three replicate wells were used to determinate each data point 
and three independent experiments were carried out in different days.  
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data obtained clearly demonstrate that the viability of the bend.3 cells is maintained with a small 
decrease in the highest concentration in the cells treated with free vancomycin. The results for 
penicillin showed that no cytotoxicity effects are detected in the case of the empty liposome and 
the free antibiotic. In the data of penicillin-encapsulated liposomes we observed a small decrease 
in cell viability, though the viability remains higher than 85%. On the contrary, in the ceftriaxone 
cytotoxicity results it is observed the maintenance of the cell viability in most of the 
concentrations tested in the three compounds: the free antibiotic, the ceftriaxone-encapsulated 
liposome and the empty liposome. However, at the highest concentration were verified a sudden 
decrease of the cell viability in the cells treated with free antibiotic and with ceftriaxone-
encapsulated liposomes. This toxicity seems to be due to the antibiotic toxicity since the empty 
liposome does not affect the cell viability.   
The cytotoxicity assays are required for estimation and characterization of potentially toxic 
effects of the developed liposomes [110], meaning that when in the organism, healthy living brain 
cells will not be induced in cell death. The results discussed above lead to conclude that the 
antibiotics-encapsulated liposomes are safe nanocarriers, allowing to proceed for the development 
of the immunoliposome, knowing that no toxic effects will be detected. 
3.8 Development of an immunoliposome - Expression and purification of FC5 and G3 to 
liposome conjugation 
After validating the antimicrobial efficacy of the liposomes in S. pneumoniae strains, the next 
step was the coupling of the target technology to cross the BBB and reach the bacteria. The 
development of an immunoliposome started with the expression and purification of the antibodies 
chosen to cross the BBB. High quantities of protein containing a His-Tag were recovered from 
the lysate extract using an IMAC. The elution fractions were analyzed by SDS-PAGE followed 
by coomassie staining and western blot (figure 3.18).  
The coomassie staining method is required to evaluate the protein purity. In the obtained results 
(figure 3.18A/B) it was possible to observe the intended antibody with a molecular weight of 
Figure 3.18: SDS-PAGE with the several fractions collected from IMAC purification. (A) Coomassie staining 
technique with the results of G3 purification; (B) coomassie staining with the FC5 purification results; (C) western blot 
with the results of G3 purification; (D) western blot with the results of FC5 purification. 
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15kDa in the fractions collected in both sdAb purifications. The flow through (FT) corresponding 
to the protein unbound to the column does not contain the sdAb, meaning that the antibodies 
successfully bound to the column. The analyzed fractions corresponding to the higher 
concentration registered on the IMAC purification contain a high number of undesirable proteins 
due to the elution of the proteins weakly bound to the column. Simultaneously, a western blot 
was performed with the collected fractions in order to reveal the desired protein, using an Anti-
His as primary antibody for the process. This revealed the presence of a protein of about 15 kDa, 
in both cases corresponding to the desired single domain antibodies. To improve the purity of the 
antibodies, a second chromatography was performed. This time, a size exclusion chromatography 
was performed in order to separate the proteins according to their size. The collected fractions 
were also analyzed in a SDS-PAGE by two techniques: coomassie staining and western-blot. The 
results obtained are shown in figure 3.19. 
Aiming to obtain the antibodies with high purity, the results presented above shown that the SEC 
was successfully performed. In the coomassie staining results (figure 3.19A/B) is possible to 
observe that the undesired proteins presented in the fractions collected from the IMAC were now 
eliminated, since in both purifications (FC5 and G3) only one band is present in the coomassie 
gel. The western blot was made to confirm the presence of the intended antibodies, using anti-His 
as primary antibody shown that in G3 purification (figure 3.19 C) all the fractions analyzed 
contain the antibody. However, in FC5 western blot (figure 3.19 D) three fractions do not contain 
the desired antibody.  
The expression and purification of the sdAb was successfully achieved enabling to proceed with 
the immunoliposome development. The following step was the conjugation of the antibodies to 
the liposome surface, to efficiently create an immunoliposome. 
 
Figure 3.19: SDS-PAGE with the several fractions collected from SEC purification. (A) Coomassie staining 
technique with the results of G3 purification; (B) coomassie staining with the FC5 purification results; (C) western blot 
with the results of G3 purification; (D) western blot with the results of FC5 purification. 
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3.9 SdAb (FC5 and G3) coupling to the liposome surface – Biotin approach 
The coupling of the sdAb to the liposome surface was performed using two different approaches: 
the biotin approach and the maleimide approach. Regarding the biotin approach the distinguishing 
feature that lead to consider a promising method was the affinity of the noncovalent interaction. 
The affinity is only compared with systems involving ligand metal ions. The reaction between 
the biotin and streptavidin is almost irreversible ensuring a good conjugation between the 
liposome and the sdAb’s. 
The biotin method starts with the antibody biotinylation where the sulfo-NHS-LC-biotin supplied 
with the biotinylation kit (material and methods section) possess an active ester group that reacts 
with the primary amines or the -amino of the lysine in an antibody (figure 3.20). For each lysine 
residue, this reaction results in a molecular weight increase of 339.161 Da, as previously 
demonstrated [111]. The determination of the best ratio for the sdAb biotinylation reaction was 
performed using FC5 that contains 41 lysine residues.  
 
The analysis of the biotinylated antibodies by SDS-PAGE is presented on figure 3.21. In the first 
assay 4 different sdAb:biotin ratios were tested and the sdAb biotinylations were confirmed by 
biotin detection in western blot analysis employing HRP-conjugated streptavidin The ligation 
between the sdAb and the biotin occurred in all the ratios tested since biotin was detected in all 
the reactions. However, a significant increase of the molecular weight between the several ratios 
tested was not verified, meaning that the biotinylation level was similar in all the ratios. 
Additionally, it was also possible to conclude that the biotinylation was not very high considering 
that the molecular weight was similar to the control.  
 
 
 
 
 
 
 
Figure 3.20: Chemical reactions involved in antibody biotinylation. 
Figure 3.21: Optimization of the sdAb-biotin ligation. The first assay was performed with four 
different ratios and the second assay was performed with the best ratio obtained in the first assay 
and a second ratio. 
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A second assay was performed using two ratios 1:20 and 1:30 and it was verified that the ratio 
1:30 had a better incorporation level since the detection is stronger for the same antibody 
concentration. An increase of the molecular weight was also observed suggesting that the number 
of biotin molecules linked to the lysine residues was higher. The biotinylation level should be 
enough to the subsequent reactions, which was achieved in the 1:30 molecular ratio 
The biotinylation was also performed with G3, a sdAb that contains 44 lysine residues. We 
expected that using the same ratio used for FC5, the biotinylation level remained equivalent to 
the results obtained above, which is proven by the WB presented in figure 3.22. 
 
 
 
 
 
 
 
Since biotinylation of both sdAb was successfully achieved, the next step was the conjugation of 
the biotinylated sdAb to the streptavidin in order to be possible to link to the biotinylated 
liposomes. The two processes were made in one step with the incubation with streptavidin 
followed by the incubation with the liposomes containing PEG-biotin. The ratio sdAb: biotin 
(considering the ratio of biotin presented in the liposomes – supplementary information) was 
optimized in order to find the best ratio. The results were evaluated in a western blot after the 
separation of the sdAb unbound to the liposome. 
The western blot showed that the best ratio to link the biotin-liposomes to the sdAb was 
3:1(sdAb:biotin), since in the ratio 1:1, it was not detected sdAb bound, in either of the sdAb 
tested. In the 3:1 ratio, ligation of both sdAb to liposomes could be detected. Simultaneously, the 
best ratio was also tested by an ELISA to confirm the ligation of the sdAb to the liposome, using 
as capture antibody anti-PEG to link to the liposomes and as detection antibody anti-His to 
efficiently detect the antibodies.  
Figure 3.22: FC5 and G3 biotinylation. The biotinylation process was 
performed using the best ratio previously evaluated: 1:30. The results were 
analysed in a western blot comparing with a positive control: 100 ng of the sdAb 
previously purified. 
Figure 3.23: Optimization of the liposome-antibody conjugation. The ratio sdAb: PEG-biotin was optimized with two 
different ratios: 3:1 and 1:1 and analysed in a western blot using anti-his as primary antibody 
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The ELISA data (figure 3.24) confirmed the results 
obtained in the western blot. We used as negative control 
the liposome-PEG (without sdAb and biotin). The two 
developed immunoliposomes presented a higher 
absorbance when compared with the negative control, 
proving the success of the conjugation of the sdAb to the 
biotin-liposomes, since it was confirmed the presence of 
the liposomes and the antibodies in the reaction solution. 
The results obtained showed that development of the  
immunoliposomes using the biotin approach was 
successfully achieved. However, it is also important to 
determine the efficiency of the ligation between the sdAb 
to the biotin-liposomes.  The sdAb attachment efficiency 
was determined by the Bradford method (supplementary 
information), quantifying the unbound antibody and 
comparing with the quantity of initial antibody added to 
the reaction, since the quantification of the antibody 
attached to the liposome is uncertain owing to streptavidin interference.  
Table 3.6: Yield of sdAb (G3 and FC5) attachment on liposomes prepared by the biotin approach. The yield was 
calculated after measuring the sdAb by a bradford technique. Each value is the mean from n samples (and the standard 
deviation is presented) 
 
sdAb-liposome 
Yield of sdAb 
attachment (%) 
 
Range of values 
 
n 
G3-liposome 75±12 68.2-82.5 3 
FC5-liposome 70 ±7 63.4-76.8 3 
 
The obtained yield attachment for the two sdAb tested (table 3.6) was 70% and 75%, showing a 
high ligation efficiency between the biotin liposome and the antibodies. This proves that the biotin 
approach is promising for the development of immunoliposomes. These values are similar to a 
recent study where the same procedure was used to develop immunoliposomes [112]. 
3.10 SdAb (FC5 and G3) coupling to the liposome surface – Maleimide approach 
The maleimide approach is widely used in bioconjugation and is based on the reaction between a 
sulfhydryl group with maleimide groups. The maleimide is conjugated in the liposome 
formulation and the sulfhydryl group is added to the sdAb after the reaction with the Traut’s 
reagent. The process starts with the thiolation of the sdAb followed by the incubation with the 
Figure 3.24: ELISA confirming the 
conjugation of the sdAb with the 
liposomes. The presented results presented 
are the means of three independent assays 
(±standard deviation). 
Figure 3.25: Optimization of the liposome-antibody conjugation. The ratio sdAb: PEG-maleimide was optimized 
with two different ratios: 3:1 and 1:1 and analysed in a western blot using anti-his as primary antibody 
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liposomes, containing PEG-maleimide. The ratio sdAb: maleimide (considering the ratio of 
maleimide presented in the liposomes – supplementary information) was optimized in order to 
find the best ratio. The results were evaluated in a western blot after the separation of the sdAb 
unbound to the liposome. 
In the western blot it is possible to observe that the best ratio to link the maleimide-liposomes to 
the sdAb is 3:1(sdAb:maleimide), since in the ratio 1:1 it was only detected sdAb bound in G3, 
while in FC5 the reaction did not occur. In the ratio chosen, we detected the ligation in both sdAb 
tested.  The efficiency of the sdAb attachment in the ratio 3:1 was also determined. The obtained 
results are presented in table 3.7.  
Table 3.7: Yield of sdAb (G3 and FC5) attachment on liposomes prepared by the maleimide approach. The 
yield was calculated after measuring the sdAb by a bradford technique. Each value is the mean from n samples (and 
the standard deviation is presented) 
 
sdAb-liposome 
Yield of sdAb 
attachment (%) 
 
Range of values 
 
N 
G3-liposome 78±2 76.8-80.5 3 
FC5-liposome 45 ±3 42.5-48.3 3 
 
The calculated yield attachment for the sdAb tested was equal to 78% in the case of G3 and 45% 
in the case of FC5, showing a high ligation efficiency between the maleimide liposome and G3. 
FC5- maleimide liposomes presented the lowest efficacy when compared to all the 
immunoliposomes developed. 
According to the results presented in this chapter the development of the immunoliposomes 
aiming to cross the BBB was successfully achieved, by two methods that differ in the conjugation 
properties. Since the yield of the conjugation techniques was confirmed to be promising, it was 
necessary to test the ability of the immunoliposomes in crossing the BBB. 
3.11 In vitro BBB model 
The BBB model was performed in order to determine the ability of the developed 
immunoliposomes in crossing the BBB. In this model brain endothelial cells were grown on the 
apical size of a porous membrane positioned between the apical side and the basolateral size. Two 
parameters were evaluated along the studies: the translocation of the immunoliposomes that was 
determined by fluorescence of the encapsulating rhodamine in the liposomes, and the BBB 
integrity, through FD40 translocation (material and methods section).   
The first assay was carried out using the two sdAb in study, and the immunoliposomes previously 
developed by the two methods (biotin and maleimide) with 90 minutes of incubation.  
Regarding the sdAb, the western blot results 
(figure 3.26) showed that after 90 minutes, 
both sdAb tested translocate the BBB, 
independently of the translocation mechanism, 
since it was detected in the basolateral side. 
The translocation of the two antibodies was 
similar. Furthermore, the analysis of the BBB 
integrity showed that the sdAb had minimal 
influence on the BBB model permeability 
(table 3.8).  
sdAb BBB integrity (%) 
G3 88.8 ± 3.77 
FC5 93.8 ± 0.9 
Table 3.8: Integrity of BBB in vitro model, after 
translocation of the sdAb in study (G3 and FC5). 
The yield was calculated using FD40 as presented in 
material and methods sections. Each value is the mean 
from 2 samples (and the standard deviation is 
presented) 
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 Concerning the immunoliposomes, the results (figure 3.27) showed that after 90 minutes of 
incubation, a low percentage of the immunoliposomes added to the apical side translocate the 
BBB. The translocation of FC5-biotin-Lip and G3-biotin-LIP was 3.8 and 4.1 times higher 
respectively, than the biotin-lip without the sdAb. Instead, the translocation of FC5-maleimide-
Lip and G3-maleimide-Lip was 1.2 and 1.7 times higher than the maleimide-lip without the sdAb, 
respectively(figure 3.27). The evaluation of the translocation between the two different 
immunoliposomes developed led us to conclude that the biotin-liposomes were more efficient in 
crossing the BBB when compared with the maleimide liposomes. Furthermore, the evaluation of 
BBB integrity (table 3.9) revealed that all immunoliposomes developed had minimal effect on 
the barrier permeability proving to be a promising system for drug delivery to the brain. However, 
the translocation of the immunolipomes remains low and in order to improve the translocation a 
new assay was performed with higher incubation times, using the immunoliposomes developed 
though biotin conjugation. A incubation time higher than 90 minutes can be necessary for the 
translocation of nanocarriers with a higher size than the sdAb as already discussed in previous 
studies [113]. 
 
 
 
 
 
Lip 
 
BBB integrity (%) 
Control (+) 89.4 ± 1.0 
Biotin-Lip 94.7 ± 1.1 
FC5-Biotin-
Lip 
90.6 ± 0.9 
G3-Biotin-Lip 87.9 ± 0.5 
Mal-Lip 93.2 ± 4.2 
FC5-Mal-Lip 95.5 ± 1.4 
G3-Mal-Lip 88.9 ± 5.7 
Figure 3.26: Translocation of the sdAb across a BBB model in the 90 minutes incubation time. The collected apical 
and basolateral sides were analysed in a western blot using anti-His (1:3000) as primary antibody. Two replicates wells 
for each sdAb were analysed. 
Figure 3.27: Percentage of BBB translocation by immunolipomes 
developed by maleimide conjugation. (A) immunoliposomes 
developed by biotin conjugation (B)The percentageof translocation 
was, determined by fluorescence intensity measurements of 
rhodamine-loaded liposomesdetection. A one-way ANOVA statistical 
test followed by a Dunnet’s test was used to compare each 
immunoliposome fluorescence measurement with the respective 
liposome without sdAb (** p≤0.01; n.s., not significant); The values 
were obtained from duplicates of one experiment. 
Table 3.9: Integrity of BBB in vitro model, 
after translocation with an incubation 
time of 90 minutes of the 
immunoliposomes in study. The yield was 
calculated using FD40 as presented in 
material and methods sections. Each value is 
the mean from 2 samples (and the standard 
deviation). 
 
A B 
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3.12. In vitro BBB model – incubation time optimization 
Aiming to improve the translocation of the immunoliposomes, several incubation times were 
tested. The immunoliposomes developed through the biotin method were added to the apical side 
of the BBB model and the basolateral side was collected after 3, 6 and 24 h of incubation. The 
translocation was measured using rhodamine fluorescence and it was also analysed by western 
blot using Anti-His (1:300) as primary antibody.  
The results (figure 3.28) showed that the highest translocation percentage was observed at 24 
hours of incubation. With this incubation time the translocation reached a maximum of 
29.3±6.5% using the G3-biotin-liposome, which is 9.4 times higher than the liposomal 
formulation without the sdAb. Concerning the liposome linked with FC5 the translocation is 
about 12.9±1.6%, that is 4.2 times higher than the liposomal formulation, which is similar to the 
results previously obtained in the incubation time of 90 minutes. Independently of the incubation 
time, the immunoliposome with G3 presented consistently a better translocation when compared 
with FC5 immunoliposomes, which can be due to the translocation mechanism of G3 that is still 
unknown. 
Figure 3.29: Translocation of the sdAb across a BBB model with several time points: 3,6 and 24 hours. 
The collected apical and basolateral sides were analysed in a western blot using Anti-His (1:3000) as primary 
antibody. Two replicates wells for each sdAb were analysed. 
29.3 % 
12.9 % 
6 hours 
Figure 3.28: Percentage of translocation for immunolipomes developed by biotin approach at 3, 6 and 24h 
incubation times. The percentage was determined by rhodamine fluorescence intensity detection. A one-way 
ANOVA statistical test followed by a Turkey’s test was used to compare each immunoliposome fluorescence 
measurement with the respective liposome without sdAb and the two sdAb between each other (**** p < 0.0001; 
*** p≤0.001;** p≤0.01; * p≤0.05; n.s., not significant); The values were obtained from duplicates of one 
experiment. 
3 hours 
24 hours 
3.1 % 
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The western blot results (figure 3.29) of the three time points support the fluorescence data. The 
incubation time with the best results was the 24 hours where the immunoliposome was detected 
on the basolateral side collected in both cases (with FC5 and G3), in all the duplicates. In the first 
time point (3 hours) it is only achievable to detect the immunoliposome in the basolateral side in 
G3 immunoliposomes. Additionally, in the incubation time of 6 hours, it was only possible to 
detect the G3 immunoliposomes in the apical side which implies that the translocation was 
negligible. The absence of bands in the both sides of the in vitro BBB model in the case of FC5 
immunoliposomes can be a consequence of the loss of the His-Tag during the conjugation 
procedure.  
Based on the western blot and the fluorescence measurements results, the incubation time of 24 
hours revealed to be the most adequate incubation time for the translocation of the 
immunoliposomes through the BBB. Noteworthy, the translocation of G3 immunoliposomes 
through the BBB on this incubation time showed a high in vitro efficacy, revealing these 
immunoliposomes as a promising therapeutic for S. pneumoniae overtaking the obstacle in 
translocate the BBB.  
Additionally, the integrity of the BBB does not present any effect on the permeability, validating 
the immunoliposomes in a higher incubation time (table 3.10). 
 
 
 
 
 
 
 
 
 
 
 
Therefore, to further ensure the results obtained above, two independent assays were performed 
in the same conditions used before, with an incubation time of 24 hours. The results of these 
assays (figure 3.30) showed that both immunoliposomes have a high translocation, about 
24.8±1.2% for FC5 immunoliposomes and 34±4.1% for G3 immunoliposomes.  
 
Lip BBB integrity (%) 
Control (+) 90.4 ± 1.0 
Biotin-Lip (3h) 87.4 ± 0.3 
FC5-Biotin-Lip (3h) 94.1 ± 5.2 
G3-Biotin-Lip (3h) 97.9 ± 0.8 
Biotin-Lip (6h) 87.4 ± 0.3 
FC5-Biotin-Lip (6h) 95.8 ± 2.9 
G3-Biotin-Lip (6h) 90.7 ± 0.6 
Biotin-Lip (24h) 95.2 ± 1.0 
FC5-Biotin-Lip (24h) 92.2 ± 3.0 
G3-Biotin-Lip (24h) 95.2 ± 1.5 
Table 3.10: Integrity of BBB in vitro model, after translocation with an incubation time of 3, 6, and 24 
hours of incubation with the immunoliposomes in study. The integrity was calculated using FD40 as 
presented in material and methods sections. Each value is the mean from 2 samples (and the standard deviation). 
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Chapter 4 - Integrated analysis, main conclusions and future perspectives. 
Bacterial meningitis caused by S. pneumoniae is a severe cause of meningitis, affecting all ages 
and often resulting in sequelae or death of the patient. The main challenge for the treatment of 
this disease is the low permeability of the BBB to most of the pharmaceuticals. Therefore, the 
treatment of pneumococcal meningitis requires the incorporation of a target technology for the 
BBB and an antimicrobial compound to fight bacteria.   
Nanocarriers are the most commonly studied as drug delivery vehicles for BBB translocation with 
the advantage of selectively targeting the brain [114]. The approach presented in this study has 
the purpose to develop an immunoliposome as a drug delivery system for the treatment of 
pneumococcal meningitis. Otherwise stated, the treatment purpose combines the antibiotic’s 
encapsulation as the antimicrobial compound and the conjugation of a sdAb to the liposome 
surface, aiming to target the BBB.  
The first step of this study was the validation of the antimicrobial efficiency of the liposome 
encapsulated with antibiotic against S. pneumoniae TIGR4 (reference strain). This task was 
performed by determining the minimum inhibitory concentration of the three liposome-
encapsulated antibiotics: ceftriaxone, penicillin and vancomycin. The results for this assay 
confirmed the antimicrobial efficacy of the three liposomal-encapsulated formulations and were 
interpreted as positive indicators to the development of a treatment of a pneumococcal meningitis. 
The MIC of the liposome-encapsulated antibiotics was higher than the free antibiotics in all cases, 
however, it is important to note that these encapsulated liposomes represent a better option for 
clinical treatment since they possess lower cytotoxicity and a targeting technology [115]. Between 
the three different formulations the vancomycin-encapsulated liposomes were the most efficient 
ones. This is proved since the differences between the MIC of the free antibiotic and the 
Figure 3.30: Percentage of translocation for immunolipomes developed by biotin approach at 24h incubation 
time. The percentage was determined by rhodamine fluorescence intensity detection. A one-way ANOVA statistical 
test followed by a Turkey’s test was used to compare each immunoliposome fluorescence measurement with the 
respective liposome without sdAb and the two sdAb between each other (** p≤0.01; * p≤0.05; n.s., not significant); 
The values were obtained from the mean of  duplicates of two independent experiment and the standard deviations are 
presented.  
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vancomycin-encapsulated liposome is much lower when compared with other formulations. 
However, the comparison between the efficacy of the three encapsulated-liposomes have shown 
that the ceftriaxone-encapsulated liposomes and the penicillin-encapsulated liposomes have a 
lower MIC, considering a promising option for pneumococcal meningitis treatment. 
In order to validate the liposomal formulations their potential was also evaluated in clinical 
isolates. Each described serotype holds different capsule characteristics. The interaction between 
the liposome and the bacterial capsule seems to occur, since different serotypes resulted in 
different antimicrobial efficacy of the antibiotics-encapsulated liposomes. For example, serotype 
1 has a zwitterionic capsule that can interact either with anionic liposomes or cationic. On the 
other hand serotype 7F produces neutral polysaccharides which leads to a non-charge capsule 
[116]. In summary, the differences between the polysaccharides in each CPS result in distinct 
charges. These differences interfere with the interaction between the liposome and the bacteria 
and consequently the results obtained differ according to the serotype.  In further studies, it will 
be crucial to test different liposomal formulations with singular characteristics, aiming to discover 
a formulation that enhances the interaction between the liposome and the different serotypes CPS. 
For example, the use of a fusogenic liposome, described as pH-sensitive with a high capacity to 
fuse with the bacteria membrane and promote intracellular drug release [76]. This is a promising 
approach for pneumococcal meningitis since this type of liposomes is able to interact with the 
bacteria and perhaps annul the interference of the CPS.  
Before the development of an immunoliposome the toxicity of the antibiotics-encapsulated 
liposomes was tested using cytotoxicity assays, which is considered a crucial step of any 
pharmaceutical development [117]. The results of the cytotoxicity assays proved that none of the 
developed encapsulated liposomes decreased the viability of the brain endothelial cells suggesting 
that the nanoparticle proposed is a safer way to treat pneumococcal meningitis.  
Since the antimicrobial efficacy and the safety of the developed liposomal formulations were 
tested, the following step was the development of the immunoliposome, which started with a 
successful expression and purification of the two sdAb used to conjugate in the liposomal surface: 
FC5 that is widely used to target the BBB and G3 that was selected by our laboratory as a 
promising sdAb that targets the BBB. The conjugation of the liposome and the sdAb were tested 
by two often used methods: the biotin-streptavidin method and the maleimide method. The 
development of the immunoliposome was optimized and it was possible to obtain high yields for 
this process through the two tested methods.  
The main purpose of this project was the development of an immunoliposome able to cross the 
BBB. Consequently, an in vitro BBB model was developed to evaluate the translocation of the 
immunoliposomes through the BBB. The immunoliposomes developed by the biotin method 
demonstrated a higher translocation when compared with the immunoliposomes developed by the 
maleimide method being chosen as the best conjugation method. The in vitro model was then 
optimized concerning the incubation time with the immunoliposomes, and 24 hours was selected 
as the best incubation time where the translocation is high without loss of integrity. Between the 
two sdAb used is possible to conclude that G3-immunoliposomes have a higher translocation 
when compared with FC5-immunoliposomes.  
The overall results from this work showed that an immunoliposome as a drug delivery system for 
treatment of pneumococcal meningitis is a promising approach, since it was possible to validate 
the antimicrobial efficacy of the encapsulate-liposome antibiotics against S.pneumoniae and it 
was achievable the development of an immunoliposome able to cross the BBB.  
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As in this work only the in vitro translocation of the immunoliposomes was tested, to strengthen 
these results, the execution of an in vivo biodistribution of the immunoliposomes , in which the 
translocation of the immunoliposomes through the brain will be tested along with the 
accumulation of the immunoliposomes in several organs will also prove the low toxicity of the 
developed immunoliposomes. Besides that, the biodistribution and efficacy of the 
immunoliposomes in a pneumococcal meningitis mouse model will provide important 
conclusions about the developed drug delivery system. 
 
In conclusion this work is an essential first step in the pneumococcal meningitis treatment, 
validating a novel therapeutic approach We hope that this work also contributes to the infinite 
steps required for the treatment of several brain diseases limited by the BBB impermeability. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Schematic representation of the main results of this project and the future perspectives 
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Supplementary data 
 
 
Supplementary figure 1: Linear regression and equation of absorbance of the several BSA concentrations for 
Bradford method .  
 
Unloaded liposomes containing functional PEG – PEG-Maleimide and PEG-Biotine 
Lipid compositions – DPPC:Chol:DSPE-PEG: DSPE-PEG-FA: DSPE-PEG/Biotine or 
Maleimide Molar ratio - (1.85:1.0.11:0.03:0.01)  
Supplementary table 1: Physicochemical characterization of liposomal formulations 
 
 
Formulation Mean size (nm) 
(P.I.) 
Zeta 
Potential 
(mV) 
Lipid  
Concentration 
(µmol/ml) 
Biotine 125±2 
(<0.06) 
- 3  1 20 
Maleimide 128±1 
(<0.06) 
- 2  1 20 
